Neurodegenerative stress related mitochondrial proteostasis by Fang, Lei
 Neurodegenerative Stress Related Mitochondrial 
Proteostasis 
 
Inauguraldissertation 
Zur 
Erlangung der Würde eines Doktors der Philosophie 
Vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
Von 
 
Lei Fang 
von Nanjing, China 
 
 
Basel, 2015 
 
II 
 
III 
 
  
 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von 
 
Prof. Dr. Christoph Handschin  
PD. Dr. Albert Neutzner 
Prof. Dr.Christoph Hess 
 
 
 
 
Basel, 09.12.2014 
 
 
 
Prof. Dr.Jörg Schibler 
Dekan der Philosophisch- 
Naturwissenschaftlichen Fakultät 
 
IV 
 
I 
 
Acknowledgements 
First of all, I want to genuinely thank my project supervisor PD. Dr. Albert Neutzner. He picked 
me up from literally nowhere four years ago, and offered me a great opportunity of establishing 
my research career on a very interesting and cutting edge topic – Mitochondria Maintenance. 
During the past four years, he has showed me in every aspect in his best, of how to conduct a 
scientific investigation – the initiation of research ideas, the evaluation of results, and the 
correct manner towards difficulties…… and so on. He is always kind, optimistic, full of positive 
energy, and taking good responsible for his family and employees. He is the lightening tower 
beyond the ocean, which makes me looking towards, stepping close, and staying hopeful.  
In the meantime, I want to thank my PhD committee members, my faculty representative Prof. 
Dr. Christoph Handschin and co-advisor Prof. Dr. Christoph Hess. Both of them gave me much 
support when I brought up my PhD topic to them at the beginning. And they have provided 
quite useful suggestions to optimize project, technically and theoretically as well. They have 
both showed a lot of patients and generosities to my work. 
And of course, I want to thank several important people who I have been worked with during 
my PhD life too. Dr. Med. Maneli Mozaffarieh generously offered me one keynote clinical 
research on glaucoma patients as a collaboration partner. We have done some interesting 
experiments and accomplished several important conclusions during the past one and half 
years. Prof. Dr. Josef Flammer is the head of University Eye Hospital Basel. He has involved in 
our study by sharing much precious scientific experience and helped us to improve our research 
unselfishly. Dr. Bin Fan and Dr. Jia Li from Jilin University Hospital, China, are visiting scholars in 
our lab. I am very grateful that we did some cross-principle cooperation on our research 
projects, and we managed to publish some interesting data intensively during some limited 
time.  
I want to thank Dr. Michael Abanto, Mr. Beat Erne from Microscopy Core Facility of our 
department, and Mr. Emmanuel Traunecker from FACS Core Facility of our department. They 
II 
 
helped me to study and perfect my knowledge of certain research techniques, which 
contributed extensively into my project. 
Then I also want to thank many of my lab colleagues in group ocular pharmacology and 
physiology. Dr. Claudia Bippes, Dr. Esther Gracia-Tirado, Dr. Corina Kohler, Dr. Charles Hemion, 
Dr. Anne-Sophie Benischke, and Mr. Roy Allenspach, together we helped each other, we 
learned from each other, we shared many happy moments, and we created wonderful 
memories during the past several years.   
At last, I want to thank the organizations and individuals that generously provided financial 
support to my PhD study. China Scholarship Council (CSC) provided me three years of my life 
expense in Switzerland and my flight journey to Europe. Swiss National Fund (SNF) supported 
my research cost entirely, plus one year and three month life expense in Switzerland. Velux 
Stifung, Zürich (from Dr. Maneli Mozaffarieh) supported part of my research cost and life 
expense as well. And one special thank to Mr. Roland Schärli, CEO of Lubio Science, GmbH 
(Luzern). He kindly offered me one part-time position in our department’s material stock for 
nearly 4 years, which helped me quickly join the culture mixture environment of DBM, gain 
precious managing experience, and partly supported my life expense as well.  
III 
 
Contents 
List of figures ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ V 
 
List of Tables ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ VI 
 
List of abbreviations ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ VII 
 
1 Summary ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 1 
1.1 Background  
1.2 Aim of the study  
1.3 Methods  
1.4 Results  
1.5 Conclusions  
 
2 Introductions ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 6 
 
2.1 Mitochondria ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 6 
2.1.1 Mitochondrial structure  
2.1.2 Mitochondria and energy production  
2.1.3 Mitochondria as source for reactive oxygen species (ROS)  
2.1.4 Other mitochondrial functions  
 
2.2 Mitochondrial dynamics ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 15 
2.2.1 Molecular machineries of mitochondrial dynamics in mammalian cells  
2.2.2 Importance of mitochondrial dynamics  
 
2.3 The mitochondria associated ubiquitin-proteasome system ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 20 
2.3.1 The ubiquitin-proteasome system  
2.3.1.1 UPS and organellar protein quality control  
2.3.2 MARCH5 and mitochondrial quality control  
2.3.3 P97/VCP/Cdc48  
2.3.4 Maintaining mitochondrial function  
2.3.4.1 Levels of mitochondria maintenance / quality control  
 
2.4 Mechanisms of mitochondrial quality control ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 30 
2.4.1 Molecular level of mitochondrial quality control  
2.4.2 Organelle level of mitochondrial quality control  
2.4.3 Cellular level of mitochondrial quality control  
 
2.5 Mitochondria and neurodegeneration ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 36 
IV 
 
2.5.1 Neurodegeneration  
2.5.2 Mitochondrial dysfunction and neurodegeneration  
 
3 Inactivation of MARCH5 prevents mitochondrial fragmentation and cell death in a neuronal 
cell model ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 40 
3.1 Abstract  
3.2 Background 
3.3 Results 
3.4 Discussion  
3.5 Conclusions  
3.6 Methods  
3.7 Supplementary references  
 
4 MARCH5 inactivation supports mitochondrial function during neurodegenerative stress 
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 60 
4.1 Abstract  
4.2 Introduction  
4.3 Results 
4.4 Material and methods  
4.5 Discussion  
4.6 Supplementary references  
 
5 Mitochondrial functions in neuronal cells depends on p97/VCP/Cdc48-mediated quality 
control ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 77 
5.1 Abstract  
5.2 Introduction 
5.3 Results  
5.4 Discussion 
5.5 Material and methods  
5.6 Supplementary material  
5.7 Supplementary references  
 
6 Conclusions and Outlook ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 100 
6.1 Cellular models  
6.2 Neurodegenerative stressors  
6.3 MARCH5  
6.4 p97  
6.5 Summary  
 
7 References ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ i 
 
Curriculum Vitae ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ a 
V 
 
List of Figures 
Figure 2.1 Overview of mitochondrial structure and functions ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 8 
Figure 2.2 Electron Transport Chain (ETC) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙11 
Figure 2.3 Machinery of mitochondrial dynamics ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 18 
Figure 2.4 Ubiquitin proteasome system (UPS) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 22 
Figure 2.5 Outer mitochondrial membrane associated degradation ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 25 
Figure 2.6 Levels of mitochondrial quality control ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 29 
Figure 2.7 Mechanisms of mitochondrial quality control ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 34 
Figure 3.1 Stress-induced mitochondrial fragmentation in RGC5 cells ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 45 
Figure 3.2 Inactivation of MARCH5 and Drp1 blocks pressure-induced mitochondrial 
fragmentation ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 46 
Figure 3.3 Rotenone-induced mitochondrial fragmentation is reduced following MARCH5 or 
Drp1 inactivation ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 48 
Figure 3.4 Mitochondrial fragmentation following hypoxia-reoxygenation is ameliorated by 
inactivation of MARCH5 or Drp1 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙50 
Figure 3.5 Inactivation of MARCH5 or Drp1 delays induction of apoptosis and cell death ∙∙∙∙∙∙∙∙∙52 
Figure 4.1 Neurodegenerative stress causes mitochondrial fragmentation in neuronal cells ∙∙∙∙64 
Figure 4.2 Inactivation of MARCH5 prevents stress-induced mitochondrial fragmentation ∙∙∙∙∙∙∙66 
Figure 4.3 Inactive MARCH5 supports mitochondrial interconnectivity under neurodegenerative 
stress conditions ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙68 
Figure 4.4 Mitochondrial membrane potential under neurodegenerative stress conditions is 
increased following inactivation of MARCH5 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙70 
Figure 4.5 Inactivation of MARCH5 blunts ROS production under neurodegenerative stress 
conditions ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙71 
Figure 5.1 Inactivation of p97 increased mitochondrial fragmentation under stress∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 82 
Figure 5.2 Inactivation of p97 impairs mitochondrial function during neurotoxic stress ∙∙∙∙∙∙∙∙∙∙∙ 85 
Figure 5.3 p97 is involved in mitochondrial maintenance at damaged levels below the 
thresholds for mitophagy and cell death ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙87 
VI 
 
Figure 5.4 Clearance of oxidatively-damaged mitochondrial proteins is impaired following 
inactivation of p97 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙89 
Figure 5.S1 Representative western blots for the detection of carbonylated mitochondrial 
proteins ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙97 
 
List of Tables  
Table 2.1 Mitochondrial E3 ligases and known substrates ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 24 
 
 
 
 
VII 
 
List of Abbreviations 
AAA+∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ ATPase associated with various cellular activities 
Amyloid beta ∙∙∙∙∙∙∙∙∙∙∙∙∙Aβ 
AD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Alzheimer's disease 
ADOA ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Autosomal dominant optic atrophy 
ALS ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Amyotrophic lateral scleroses 
ATP ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Adenoid triphosphate 
CCCP ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Carbonyl cyanide m-chlorophenylhydrazone 
CMT2A ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Charcot-Marie-Tooth disease 2A 
CO2  ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Carbon dioxidide 
DAT ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Dopamine transporter 
DR ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Dopamine receptor 
Drp1 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Dynamin-related protein-1 
DUB ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Deubiquitylation enyzme 
ER ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Endoplasmic reticulum 
ERAD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ER-associated degradation 
ETC ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Electron transport chain 
FAD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ ∙ Flavin adenine dinucleotide 
FTD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙  Frontotemporal dementia 
Fzo1 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Fuzzy onions homolog 
HD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Huntington's disease 
HDAC6 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Histome deacetylase 6 
HETC domain ∙∙∙∙∙∙∙∙∙∙∙∙∙Homologous to the E6AP C-Terminus 
HTG ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ High-tension glaucoma 
IBM ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Inclusion Body Myopathy 
IBMPFD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Inclusion Body Myopathy with Paget Disease of Bone and / or 
Frontotemporal Dementia 
IMM ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Inner mitochondria membrane 
IOP ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Intraocular pressure 
MAP ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Microtubule-associated protein 
MAPL ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Mitochondrial-anchored protein ligase 
MARCH5 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Membrane-associated RING-CH 
MEFs ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Mouse embryonic fibroblasts 
Mff ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Mitochondrial fission factor 
Mfn2 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Mitofusin2 
MiD49 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Dynamics protein 49kD 
MiD51 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Mitochondrial dynamics protien 51kD 
MitoYFP ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Mitochondria-targeted yellow fluorescent protein 
MOMP ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙  Mitochondrial outer membrane permeabilization 
MPP ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Mitochondrial processing peptidase 
VIII 
 
MtDNA ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Mitochondrial genome 
MtHSP60 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Heat shock protein 60kDa 
MtHSP70 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Heat shock protein 70kDa 
MtPA-GFP ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Mitochondria-targeted photoactivatable-GFP 
MULAN ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Mitochondrial ubiquitin ligase activator fo NF-κB 
NADH ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Nicotinamide adenine dinucleotide 
NO ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙  Nitric oxide 
NTG ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Normal-tension glaucoma 
O2 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Oxygen 
OMM ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ ∙∙ Outer mitochondria membrane 
OMMAD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Outer mitochondrial membrane associated degradation 
OPA1 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙Optic atrophy tpye-1 (autosomal dominant) 
OXPHOS ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Oxidative phosphorylation 
PolyQ ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Poly glutamine chains 
PolyUb ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Polyubiquitin 
PARL ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Presenilin associaterhomboid-like protease 
PD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Parkinson's disease 
PINK1 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ PTEN-induced kinase 1 
Q ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Ubiquinone 
RGC ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Retinal ganglion cells 
RNS ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Reactive nitrogen species 
ROS ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Reactive oxygen species 
SDS ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Sodium dodecyl sulfate 
SIHM ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Stress-induced mitochondrial hyperfusion 
SOD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Superoxide dismutase 
STS ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Staurosporine 
TCA ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Tricarboxylic acid cycle 
TDP-43 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ TAR DNA binding protein-43 
TH ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Tyrosine hydroxylase 
TMRE ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Tetramethylrhodamine, ethyl ester 
TOM ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Translocase of the OMM complex 
UPS ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Unbiquitin-proteasome system 
VADC ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Voltage-dependent anion channel 
VCP ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Valosin-containing protein 
6-OHDA ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 6-hydroxidopamine 
7-AAD ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 7-aminoactinomycin D 
 
 
1 
 
1 Summary 
1.1 Background  
Mitochondria are the main site of energy production in most cells. Furthermore, they are 
involved in a multitude of other essential cellular processes, such as regulating the cellular 
calcium pool, lipid metabolism and programmed cell death [1]. Healthy and functional 
mitochondria are critical to meet the fundamental needs for almost all cell types, which makes 
mitochondrial quality control (QC) very important [2]. Given the high energy demand of 
neuronal cells, their vulnerability to endo- and exogenous stressors, and their post-mitotic 
status, mitochondrial QC plays an  important role in neuronal survival with failing mitochondrial 
quality control linked to many neurodegenerative diseases such as Alzheimer's disease and 
many others [3-6]. 
Several well-orchestrated mechanisms of mitochondrial QC are in place to maintain 
mitochondrial function and to prevent cellular damage through dysfunction of mitochondria. 
Depending on the severity of mitochondrial damages, mitochondrial QC takes place on the 
molecular level, organelle level, and/or cellular level [7, 8]. Through those mechanisms 
damaged proteins are degraded, damaged mtDNA is repaired, and depolarized mitochondria 
are recycled. However when the first two mechanisms fail to reverse the damage, cellular level 
QC in form of programmed death or apoptosis takes place to limit further damage resulting 
from dysfunctional mitochondria [9]. Mitochondria are highly dynamic organelles that 
consistently undergo fusion and fission processes [10, 11]. Mitochondrial dynamics is a central 
part of mitochondrial quality control as mitophagic recycling of damaged mitochondria and as 
execution of cell death relies on the functional mitochondrial fission machinery [12, 13].  
Ubiquitin-dependent proteasome-mediated protein degradation was recently implicated in 
mitochondrial QC as well as in the regulation of mitochondrial morphology [14, 15]. As part of 
the ubiquitin-proteasome system, (Membrane-Associated-Ring-CH 5) RING finger (Really-
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Interesting-New-Gene)-domain containing transmembrane ubiquitin E3 ligase MARCH5 was 
shown to localize to the outer mitochondrial membrane (OMM) [16]. In addition, a role for 
MARCH5 in regulating mitochondrial dynamics was demonstrated through the ubiquitin-
modification of dynamin-related-protein 1 (Drp1) and some others [17]. Interestingly, 
inactivation of MARCH5 resulted in mitochondrial elongation consistent with a role of MARCH5 
in the regulation of Drp1-mediated mitochondrial fission. This feature correlates mitochondrial 
QC with the ubiquitin-proteasome-system (UPS) [18]. Furthermore, MARCH5 was shown to be 
involved in the degradation of the amyotrophic lateral sclerosis-related protein mSOD1 and the 
Joseph-Machado-disease protein ataxin 3 [19, 20]. Thus, MARCH5 function is likely involved in 
maintaining mitochondrial health in neuronal cells. 
In order for proteasomal degradation of mitochondrial proteins to take place, protein 
retrotranslocation from the mitochondrion to the cytosol where the proteasome resides is 
needed. Recently, the AAA-ATPase p97/VCP/Cdc48, an essential part of the ubiquitin-
proteasome system known to facilitate the retrotranslocation of ubiquitylated proteins for 
further degradation [21, 22], was shown to be involved in mitochondrial QC. While the role of 
p97 in mitochondrial protein QC is far from being understood, mutations in p97 were reported 
to be involved in Inclusion Body Myopathy with Paget Disease of Bone and/or fronto-temporal 
Dementia (IBMPFD) [23]. 
1.2 Aims of the study 
The main aim of this study was to further explore and elucidate mechanisms of ubiquitin 
proteasome system-mediated mitochondrial proteostasis and quality control. Despite a lot of 
progress in the last several years, the involvement of outer mitochondrial membrane- localized 
ubiquitin ligases such as MARCH5, and their involvement in OMM proteins degradation is still 
not well understood. Thus, a particular aim of the study was to further characterize the 
involvement of MARCH5 in mitochondrial maintenance. Next to ubiquitin ligases, protein 
retrotranslocation was proposed to be important for mitochondrial maintenance with the AAA-
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ATPase p97 recently connected to this process. Thus, the characterization of potential 
mitochondrial roles of p97 has been the focus of the next goal, in order to investigate the 
potential capacities of this multifunctional AAA-ATPase in mitochondrial membrane associated 
protein degradation. A last aim was to further connect mitochondrial quality control to 
mitochondrial function in neuronal-like cells and to better understand the role of 
ubiquitylation-dependent protein degradation in maintaining the health of neuronal-type cells 
especially under low stress conditions. To this end we investigated mitochondrial behavior and 
functional alternations in neuron-like cell lines in response to inactivation of MARCH5- and p97-
dependent mitochondrial QC mechanisms. 
1.3 Methods 
As model for neuronal cells, two different neuron-like cell lines were used during the 
experiments, namely RGC5 (mouse neuron-like cell) [24, 25] and SH-SY5Y (human 
neuroblastoma) cells [26]. In order to analyze the ubiquitin-mediated, proteasome-dependent 
degradation of mitochondrial proteins under normal and low stress conditions, the activity of 
two proteins, MARCH5 and p97, shown to be involved in mitochondrial protein degradation 
was blocked. To this end, cell lines expressing dominant-negative mutants of MARCH5 
(MARCH5H43W ) [16] or p97 (p97QQ ) [27]were generated by transfection and selection for stable 
expression. In order to model low level neurodegenerative stress to neuronal cells below the 
mitophagic and apoptotic threshold but likely to induce mechanisms of mitochondrial 
proteostasis, neuron-like cells were exposed to conditions of elevated pressure or hypoxia/re-
oxygenation or were treated with the known neurotoxic agents 6-hydroxydopamine [28], the 
mitochondrial complex I inhibitor rotenone [29], or the Alzheimer’s related Aβ peptide [30]. 
Confocal microscopy was used to acquire high solution images of mitochondrial morphology, 
while quantification of mitochondrial fusion and fission dynamics was performed by using a 
mitochondrial matrix-targeted photoactivatable-GFP (mtPA-GFP)-based fusion assay [31]. In 
addition, confocal life cell imaging and flow cytometry was employed to analyze other 
mitochondrial functional parameters, such as mitochondrial membrane potential, 
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mitochondrial reactive oxygen species (ROS) production, and cellular survival. A modified 
western blot technique (OyxBlot) was applied to demonstrate oxidized protein levels on 
isolated mitochondria. Unpaired, two-tailed Student’s t-test, and paired t-test with Holm 
adjustment for multiple comparisons were used to analyze the data according to different 
specific data sets. For a detailed description of the employed methods please refer to the 
material and methods section of the included manuscripts. 
1.4 Results 
Neuron-like RGC5 cells exposed to neurodegenerative stress in form of increased hydrostatic 
pressure, hypoxia-reoxygenation, and electron transport chain inhibition following rotenone 
treatment showed increased mitochondrial fragmentation rate, increased cytochrome c release 
and cell death. Expression of MARCH5H43W alleviated the mitochondrial damage  following 
exposure to stressors, by significantly (p<0.05) reducing mitochondrial fragmentation, inhibiting 
mitochondrial cytochrome c release, and preventing RGC5 cell death, in comparison to 
MARCH5 expressing cells. These effects were shown to be similar to Drp1 inactivation, which 
was previously shown to be involved in mitochondrial fission and the execution of cell death.  
(Published in PLoS One 2012;7(12):e52637) 
Furthermore, neuron-like SH-SY5Y cells exposed to neurotoxic stressors such as rotenone, 6-
hydroxydopamine, and amyloid-beta peptide were employed to investigate the role of 
MARCH5-mediated QC in neuronal cells. As for SH-SY5Y cells, expression of MARCH5H43W 
significantly inhibited mitochondrial fragmentation induced by these stressors evidenced by 
more fused and interconnected mitochondrial networks (p<0.05) compared to MARCH5 
expressing cells. In addition, MARCH5H43W expression significantly (p<0.05) prevented 
mitochondrial membrane potential depolarization, which is considered a decisive event of 
mitochondrial failure. At last, intracellular ROS levels were evaluated by using CellROX-DeepRed 
staining and quantitative confocal imaging. Consistently, MARCH5H43W expression was able to 
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lower the ROS production significantly following neurotoxic treatments (Published in Front Cell 
Neurosci 2013 Oct 10;7:176.). 
To further investigate the role of ubiquitin-dependent proteasome-mediated mitochondrial QC 
in neuronal cells, the impact of p97 inactivation in SH-SY5Y cell treated with neurodegenerative 
stressors such as rotenone, 6-hydroxydopamine, and amyloid-beta peptide (25-35) was 
analyzed. Compared to p97 expressing cells, p97QQ expressing cells displayed increased 
mitochondrial fragmentation, with additive effects observed during neurotoxic stress (p<0.01). 
Mitochondrial membrane potential level, as detected by TMRE (tetramethylrhodamine, ethyl 
ester) and evaluated by flow cytometry was significantly decreased following p97QQ expression. 
Again additive effects were found under neurotoxic stress conditions (p<0.05). ROS production 
was evaluated using the mitochondrial specific dye MitoSOX. A significant increase of 
mitochondrial ROS production was found in p97QQ expressing cells with or without treatments 
as compared to p97. In parallel, OxyBlot further confirmed increased levels of oxidized 
mitochondrial proteins in p97QQ expressing cells (p<0.05).  
Targeted mitochondrial autophagy or mitophagy occurs when mitochondrial damage cannot be 
dealt with by the molecular repair capacity degrading the entire, damaged organelle for 
recycling. Mitochondrial translocation of the ubiquitin ligase Parkin is an important step in this 
process. Thus, Parkin mitochondrial translocation assays were used to evaluate potential 
induction of mitophagic degradation under mild stress conditions and to further support the 
involvement of the proteasomal degradation system as part of mitochondrial QC (submitted to 
Front Cell Neurosci – under review). 
1.5 Conclusions  
Healthy and steady mitochondrial dynamics and QC machinery maintain mitochondrial function 
and subsequently support neuronal cell survival during endo- and/or exogenous neurotoxic 
stresses. Thus, understanding mitochondrial QC and its failing will yield important insight into 
the mechanisms of neurodegeneration. 
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2 Introduction 
2.1 Mitochondria 
One of the first descriptions of mitochondria is from more than one hundred twenty years ago. 
There, Altmann described them as independent, intracellular structures likely involved in 
energetic processes [32]. Structure analysis showed mitochondria are subcellular double 
membrane, highly dynamic and partially independent intracellular organelles existing in most 
eukaryotic cells and containing their own genomic DNA (mtDNA). Mitochondria are most widely 
known as the power plant of the cell due to their production of adenosine triphosphate (ATP) 
through electron transport chain and oxidative phosphorylation (OXPHOS) reactions [33]. 
Besides their role in energy production, mitochondria play various roles in regulating cellular 
metabolic signals, programmed cell death known as apoptosis, and calcium balancing [34].  
2.1.1 Mitochondrial structure  
As shown in Figure 2.1, mitochondria are comprised of an outer mitochondria membrane 
(OMM) and an inner mitochondria membrane (IMM). Those two membranes enclose the 
intermembrane space and separate the mitochondrial matrix which harbors the mitochondrial 
DNA from the cytosol [35]. The outer mitochondria membrane has a similar protein-to-
phospholipid ratio as the eukaryotic plasma membrane.  The inner mitochondrial membrane 
where the protein complexes of the electron transport chain (ETC) are located is highly folded 
to forming numerous so called cristae. The intermembrane space contains a different molecular 
content as the cytosol, since the OMM allows small molecules like glucose to pass though 
freely, whereas larger proteins depend on specific transporters or membrane channels to pass 
this membrane. Cytochrome c is a soluble protein which is localized in the intermembrane 
space as well. In addition to mtDNA and ribosomes, the mitochondrial matrix contains a high 
density of proteins, mostly enzymes involved in pyruvate oxidation, fatty acid β-oxidation and 
tricarboxylic acid cycle (TCA cycle), also known as Krebs cycle. Mitochondrial DNA, which 
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contains approximately 16,600 base pairs, is coding for 37 genes including 13 peptides, 22 tRNA 
and 2 rRNA unique for mitochondrial structure and function [36].  Mutations of mtDNA, either 
in the coding or the noncoding region, heteroplasmic or homoplasmic, have been linked to 
many human diseases [37]. 
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Figure 2.1 Overview of mitochondrial structure and functions 
Mitochondria are double membrane-bound organelles with an outer (OMM) and inner mitochondrial membrane 
(IMM). The mitochondrial matrix is the inner most part of mitochondria harboring mtDNA and also the enzymatic 
machinery for the tricarboxylic acid cycle (TCA cycle). The IMM is highly folded forming so called cristae in order to 
expand the membrane surface for the components of the electron transport chains (ETC). The ETC is generating 
the mitochondrial membrane potential ultimately used for the production of ATP by complex V or the F0F1-ATPase. 
Mitochondria are involved in many different functions. Mitochondrial morphology is governed by mitofusin1 and 2 
(Mfn1/2) and dynamin related protein 1 (Drp1) localized on the OMM, while optic atrophy type 1 (OPA1) is found 
in the intermembrane space and on the IMM. Ion transporters such a voltage dependent anion channel (VDAC) are 
involved in Ca2+ buffering. Cytochrome c is a small protein localized in intermembrane space as part of the ETC. 
Release of cytochrome c following certain apoptotic signals, like Bcl-2-associated X protein (Bax) cytosolic to 
mitochondria translocation, is a key trigger of intercellular apoptosis pathway. 
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2.1.2 Mitochondria and energy production 
Mitochondria are best known for their role in cellular energy conversion from food stuff to ATP, 
a form of chemical energy usable for almost every cellular reaction. During this process, 
multistep biochemical reactions are carried out mostly in the matrix. Firstly, pyruvate is 
oxidized to produce acetyl-CoA, and then citric acid cycle is applied to oxidize acetyl-CoA into 
water and carbon dioxidide (CO2). In the meantime NAD+ and FAD (flavin adenine dinucleotide) 
are reduced into NADH (nicotinamide adenine dinucleotide) and FADH2, respectively, to store 
the energy for later use. Finally, oxidative phosphorylation (OXPHOS), which is carried out by 
the electron transport chain , is responsible for transferring the energy from NADH and FADH2 
to ATP, the universal 'petroleum' of cells [38].  
The ETC consists of five large protein complexes: complex I, II, III, IV, and V, which together 
perform OXPHOS (Figure 2.2) [39]. In detail, complex I (NADH dehydrogenase, or NADH 
ubiquinone oxidoreductase) transfers the electrons from NADH to ubiquinone to form 
ubiquinol, thereby translocating protons (H+) across the membrane from the mitochondrial 
matrix into intermembrane space generating a proton gradient. Complex I is one of the main 
site  of electron leakage happens and reactive oxygen species (ROS) produces, such as 
superoxide [40], especially when its function been inhibited by specific blocker like rotenone. 
Complex II (succinate dehydrogenase) is a parallel electron transport pathway to complex I, in 
which additional electrons are transferred to quinone (QH2) from FADH2. However, no proton 
transmembrane process is conducted in this step. Complex III (ubiquinol-cytochrome c 
oxidoreductase) catalyzes the oxidation of ubiquinone and reduction of cytochrome c (from 
Fe3+ to Fe2+), and further translocates protons out to contribute the H+ gradient [41]. If complex 
III is functionally jeopardized, e.g. by antimycin A toxicity, electrons will leak to oxygen and 
contribute to ROS production as well. Complex IV (cytochrome c oxidase) removes four 
electrons from cytochrome c to oxygen (O2) to produce two molecules of water (H2O), and 
again more protons are transferred out from matrix to the intermembrane space.  F0F1-ATP 
synthase performs the final step of ETC, in which F0 acts as an ion channel that allows protons 
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flux back into the mitochondria matrix [42]. The reflux of H+ releases free energy generated 
from NADH oxidation, which subsequently been used by F1 to catalyzes ATP synthesis [43, 44]. 
The coupling of oxidative phosphorylation with electrochemical gradient release is the key step 
of ATP production [45]. 
In brief description, mitochondria ETC transports the electrons from donors (NADH and QH2) to 
final acceptor O2 through series redox reactions (see Figure 2). The energy released from the 
chemical reactions is used by the proton pumps (complex I, III, IV) to transmembranely transfer 
the H+ and to generate proton gradient. Finally the gradient potential is released via H+ reflux 
and utilized to synthesize ATP [46]. 
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Figure 2.2 Electron Transport Chain (ETC) 
The electron transport chain is composed of five complexes (complex I - V). The substrates NADH and succinate 
generated by the tricaroboxylic acid cycle - pass electrons through the ETC (I - IV) to O2 generating H2O, meanwhile 
protons (H+) are transferred out of the matrix into the intermembrane space generating an electro-chemical 
potential across the IMM to store the energy. At last,H+ flow back through complex V, also known as F0F1-ATPase, 
driving ATP production. As byproduct of OXPHOS, the ETC is involved in ROS production, which can normally be 
neutralized by local antioxidant, such as superoxide dismutase 2 (SOD2). However, overwhelming ROS production 
triggered by certain stresses will lead to oxidative stress. Complex I and complex III are the two major sites of ROS 
production. For example, rotenone specifically inhibits complex I, while antimycin A acts on complex III inducing 
ROS production.  
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2.2.3 Mitochondria as source for reactive oxygen species (ROS) 
Reactive oxygen species describe a variety of molecules and free radicals derived from oxygen, 
which are extremely reactive oxidants. ROS include free radicals such as the superoxide anion 
(O2∙-), or the hydroxyl radical (∙OH), but also non-radical oxidants such as superoxide, hydrogen 
peroxide (H2O2), and singlet oxygen (1O2) [47]. The extremely reactive and therefore short-lived 
superoxide anion is the product of a one-electron reduction of oxygen and the precursor of 
most other cellular ROS. Detoxification or dismutation of the superoxide anion (either 
spontaneously or catalyzed through superoxide dismutase) leads to the generation of H2O2, 
which is either fully reduced to water or partially reduced to the hydroxyl radical (∙OH), one of 
the strongest oxidants in nature [48]. ∙OH as one of the most potent ROS and readily reacts with 
cellular components is responsible for oxidative damage to lipids, DNA, and proteins. 
Additionally, O2∙- may react with other radicals, including nitric oxide (NO∙) [49], leading to the 
generation of reactive nitrogen species (RNS) such as peroxynitrite (ONOO−), another highly 
reactive oxidant capable of reacting with cellular components.  
ROS are a common byproduct of the cellular metabolism. As ROS are generated during oxygen 
metabolism and as mitochondria are the main cellular oxygen sink, it is no surprise that 
mitochondria are the major cellular source for ROS. Under normal physiological conditions it is 
estimated that more than 90% of the consumed oxygen is reduced to H2O by mitochondrial 
electron transport chain. While the ETC is highly efficient, nonetheless a small portion of this 
oxygen is only partially reduced leading to ROS production [50].  
ETC-linked ROS production was first reported a half century ago. It was observed that antimycin 
A-treated isolated mitochondria are producing hydrogen peroxide [51]. Further studies 
identified more mitochondrial components responsible for ROS production, including complex 
I, complex III, and other mitochondria-localized redox systems.  
Complex I is recognized as a major source of ROS in mitochondria [40]. However under normal 
conditions, the production of superoxide by complex I is negligible. But under pathological 
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conditions, large amounts of ROS are produced by complex I. It is estimated with 40% of all 
mitochondrial disorders are related to mutations of complex I subunits [52]. Parkinson’s disease 
(PD) is one of the typical examples. PD is characterized with a progressive loss of dopaminergic 
neurons and cell bodies of the substantia nigra pars compacta and nerve terminals in the 
striatum. ROS are considered as one of the main pathogenesis factors based on dopamine 
oxidation-related metabolic pathways. Under physiological circumstance, oxidative 
deamination of dopamine by monoamine oxidase produces hydrogen peroxide [53]. In the 
pathological pathway, dopamine can be oxidized non-enzymatically by superoxide forming 
dopamine quinone which will be reduced by mitochondrial complex I to generate semiquinone 
followed by a transfer of its electron to molecular oxygen to form superoxide, completing a 
vicious oxidative cycle [54].  Both somatic and mitochondria DNA point mutations might cause 
complex I dysfunction, thus subsequently linking ROS-mediated damage to neurodegenerative 
disorders such as Leber’s hereditary optic neuropathy (LHON), Leigh’s syndrome (LS), and 
mitochondrial encephalomyopathy, lactic acidosis, and stroke like episodes (MELAS) [40]. 
Complex II does not seem to be a the main contributor to mitochondrial ROS generation [55],  
partly because succinate levels, the substrate of complex II, are relatively low in tissue. 
However, isolated mitochondria oxidizing succinate at high concentration did produce H2O2 
under in vitro conditions [56]. Under pathological conditions, evidence points to a correlation of 
complex II deficiency and increased ROS production. During drug-induced apoptosis, 
intracellular pH environment becomes significantly acidic impairing complex II activity and 
resulting in ROS generation [57]. On the molecular level this likely results from the dissociation 
of SDHA (flavoprotein subunit) and SDHB (iron-sulfur protein-containing part) subunits from the 
membrane-bound components of complex II causing single-electron reduction of oxygen by 
these reduced iron-sulfur clusters [58]. In addition, complex II dysfunction is one hallmark of 
Huntington’s disease (HD). Interestingly, treatment with 3-Nitropropionic acid, an irreversible 
inhibitor of complex II activity, induces HD-like symptoms along with increased ROS generation 
[59, 60]. 
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Complex III accepts reduction equivalents originating from complex I and complex II and 
processes them with the Q-cycle mechanism. In brief, the cycle starts with ubiquinol releasing 
its proton to the IMS and donating one electron to an iron-sulfur protein, producing one 
semiquinone on the outer side of the IMM. Semiquinone (Q-∙) continuously passes these 
electrons to hemes of cytochrome bL, and then to cytochrome bH. Cytochrome bH reduces 
ubiquinone to generate ubisemiquinone followed by its further reduction by a second electron 
and protonation [61]. Under physiological conditions, the fast oxidation rate of Q-∙ gives it less 
chance of losing electrons and thus contributing to ROS production. However, if the flow of 
electron through the complex III is stalled e.g. following application of complex III inhibitors 
such as antimycin A, myxothiazol, or stigmatellin, semiquinone levels are elevated resulting in 
more opportunities to donate single-electron to reduce oxygen [62-64].  
Aside of complex I and III as the major production site of mitochondrial ROS, also complex IV is 
able to generate ROS [65]. Complex IV, also called cytochrome c oxidase, is a protein-
phospholidpid complex containing four redox centers (CuA, cyt. a, cyt. a3 and CuB) involved in 
electron transport and the conversion of oxygen to water. During this process, several ‘peroxyl’ 
and ‘ferryl’ intermediates are produced, which are considered as potential sources of free 
radicals [65]. However, sophisticated defense mechanisms have been developed to protect the 
complex IV, including regulating ROS generation and removal [66]. In vitro mitochondrial 
ischemia/reperfusion experiment showed significant increase of ROS production, and complex 
IV has been suggested to contribute around 30-35% of total superoxide [67].  
2.1.4 Other mitochondrial functions 
In addition to metabolic process and energy production, mitochondria play important roles in 
many other cellular events. First of all, activated by various signal molecules and modulated by 
proteins of the Bcl-2 family, mitochondria release cytochrome c from the IMM into the cytosol 
through the opening of certain channel on the outer mitochondria membrane. This step of 
cytochrome c release is considered the step-of-no-return in the induction of apoptosis [68, 69]. 
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Secondly, mitochondria have the ability of storing calcium in their matrix compartment, thus 
serving as a major calcium buffering system of the cell. Furthermore, mitochondria are the 
major source of ROS, thus, playing an important role in ROS-related signaling events [70]. 
2.2 Mitochondrial dynamics 
The word mitochondrion stems from the ancient Greek mitos (meaning thread) and chondrion 
(meaning granule). This name aptly describes the primary observation of the heterogeneous 
morphologic appearance of these organelles - sometimes bean-shaped or granule-like while 
other times elongated, thread-like [71]. These early insightful observations of the polymorphic 
nature of mitochondria are nicely confirmed by modern live cell imaging techniques using 
mitochondria-targeted fluorescent proteins to follow mitochondrial morphological changes in 
vivo.  Mitochondrial morphology is less static as previously appreciated based on electron 
microscopic analyses, with mitochondria continuously changing their shapes through fission 
and fusion [3]. Thus, mitochondria are highly dynamic organelles constantly changing in sizes, 
shape, and numbers. And interestingly, dynamic behavior of mitochondria is linked to the 
function and also dysfunction of these organelles [72, 73] . 
2.2.1 Molecular machineries of mitochondrial dynamics in mammalian cells 
Mitochondrial morphology is governed by two distinct processes, mitochondrial fission or 
division of mitochondrial tubules and the fusion of mitochondria. Balanced mitochondrial 
fission and fusion together result in a steady-state morphology. Fusion of mitochondrial tubules 
necessitates the fusion to two sets of membrane without jeopardizing organellar integrity. As 
shown in figure 2.3A, three large GTPases are responsible for mitochondrial fusion. Mfn1 and 
Mfn2, two large transmembranane GTPases located on the OMM, are necessary for outer 
mitochondrial membrane fusion [74, 75]. Mouse gene knock out models have been established 
as strong supportive evidence. Single knockout mouse embryonic fibroblasts (MEFs) lacking 
either Mfn1 or Mfn2 demonstrated significantly higher fragmented mitochondria as compared 
to control MEFs, while double knock out of both Mfn1 and Mfn2 resulted in the completed loss 
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of mitochondrial fusion representing small fragmented mitochondria [76].  Interestingly and in 
addition to mitochondrial fusion, Mfn2 is involved in the formation of mitochondria – 
endoplasmic reticulum (ER) membrane contact sites [77, 78]. While fusion of the OMM is 
governed by the mitofusins, fusion of the IMM is under control of optic atrophy tpye-1 (OPA1), 
also a large GTPase located in the intermembrane space and on the IMM.  OPA1 was identified 
through human genetic studies, as its mutation results in autosomal dominant optic atrophy 
(ADOA), a disease associated with retinal ganglion cells degeneration resulting in optic nerve 
atrophy and ultimately blindness [79-82]. In OPA1 knock down cells, highly fragmented 
mitochondria have been observed, as well as severe disorganization of mitochondrial cristae. In 
addition, loss of OPA1 results in serious impairment of mitochondrial function, such as reduced 
respiratory capacity, but also increased sensitivity to apoptosis [83, 84]. Experiments on skeletal 
myocytes and cerebellar Purkinje cells have showed that lacking of OPA1 or mitofusins 
demonstrated severe decline in respiration functions [85, 86]. 
Mitochondrial fission on the other hand is mediated by dynamin-related protein-1 (Drp1) [87]. 
Upon mitochondrial fission, Drp1 is recruited from a large cytosolic pool of Drp1 to 
mitochondria. The recruitment of Drp1 to future scission sites is under control of a group of 
outer mitochondrial membrane proteins, such as the mitochondrial fission factor (Mff), 
mitochondrial dynamics protein 49kD (MiD49) and mitochondrial dynamics protein 51kD 
(MiD51), as well as hFis1 [88, 89]. These OMM-anchored proteins serve as receptors of Drp1 on 
out mitochondria membrane, similar to yeast Fis1 [90]. The analyses of dominant negative 
mutants of Drp1 (Drp1K38A) and RNA interference experiments strongly support the function of 
Drp1 in mitochondrial fission. Loss of Drp1 activity results in elongated and entangled 
mitochondrial morphology, and confers resistance to mitochondrial fragmentation stimuli, such 
as treatment with the mitochondrial uncoupler CCCP (carbonyl cyanide m-
chlorophenylhydrazone) [91]. Also, loss of Drp1 activity greatly increases resistance to 
apoptotic stimuli further connecting mitochondrial morphology to the execution of apoptosis. 
Drp1 is the target of several regulatory mechanisms, as it is crucial for maintaining a balanced 
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mitochondrial network. Drp1 activity is impacted by several post-translational modifications:  
Phosphorylation by cyclin B1-CDK1 activates Drp1 during cell mitosis; nitric oxide (NO) activates 
Drp1 through S-nitrosylation [92]; mitochondrial-anchored protein ligase (MAPL) can regulate 
Drp1 activity by SUMOylation [93]; and membrane-associated RING-CH (MARCH5) as well as  
Parkin are both ubiquitin ligases which can regulate Drp1 activation and degradation through 
ubiquitylation [16, 17, 94, 95]. (Fig. 2.3B) 
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Figure 2.3 Machinery of mitochondrial dynamics 
Mitochondrial fusion (A) is mediated by three large membrane GTPases. Mfn1and Mfn2 both located on outer 
mitochondrial membrane (OMM) mediate fusion of the OMM, while OPA1 governs fusion of the inner 
mitochondrial membrane (IMM). Mitochondrial fission (B) is depended on recruitment of Drp1 from the cytosol to 
the OMM by a group of cofactors, including mitochondrial fission factor (Mff), mitochondrial dynamics protein 
49kD (MiD49), mitochondrial dynamics protein 51kD (MiD51), or hFis1. Posttranslational modifications of Drp1, 
such as phosphorylation by cyclin B-CDK1, ubiquitylation by Parkin and membrane-associated RING-CH 5 
(MARCH5), or SUMOlytion by mitochondrial-anchored protein ligase (MAPL) further regulate the activity of Drp1 
and thus modulate the mitochondrial fission rate. 
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2.2.2 Importance of mitochondrial dynamics 
Mitochondrial fusion and fission are two opposing but exquisitely balanced processes 
appropriately maintaining the shape, size and number of mitochondria. Beyond simply 
maintaining mitochondrial morphology, fusion and fission processes are considered extremely 
critical to many functional features of mitochondria.  
First of all, continuously mitochondrial fusion and fission promotes content mixture effectively 
between individual mitochondrial subunits. Considering the relative instability of mtDNA and 
the heterogenic pool of mitochondria, the frequent exchange of content promoted by frequent 
mitochondrial fusion provides opportunities for repairing mutated mtDNA via complementation 
or for compensating of respiratory capacity by supplying functional mitochondrial proteins to 
damaged mitochondria. Thus, fusion of a damaged with a functional mitochondrial subunit 
provides a chance to repair mitochondrial function [96-98]. And indeed it was shown, that 
blocking mitochondrial fusion results in loss of mitochondrial fidelity in mammalian cells and 
complete loss of cristae structure and respiratory capacity in budding yeast [99-101] . Just as 
mitochondrial fusion is essential for maintaining mitochondrial function, the fission process is 
also involved in mitochondrial maintenance. Mitochondrial fission promotes the segregation of 
functional from damaged mitochondrial contents, and facilitates the degradation of damaged 
mitochondria beyond repair [102, 103]. Taken together, mitochondrial dynamics aids 
mitochondrial quality control system by enabling rescue and repair of mitochondrial through 
fusion-mediated complementation and also by promoting segregation of damaged 
mitochondria from the healthy mitochondrial network. 
Connected to its function in mitochondrial complementation and repair, mitochondrial 
dynamics promotes adaptation to certain types of stresses. In cellular experiments, nutritious 
starvation or exposure to UV light induces highly elongated, interconnected mitochondria, a 
phenomenon described as stress-induced mitochondrial hyperfusion (SIMH) [104]. 
Interestingly, SIMH is accompanied by elevated mitochondrial membrane potential and 
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increased ATP production [104]. SIMH depends on the function of Mfn1 and OPA1, and confers 
a certain resistance to additional stress-related insults [105, 106].  
Also connected to the maintenance of mitochondrial network integrity is the mitophagic 
destruction of damaged mitochondrial subunits. Enhanced mitochondrial fission as result of a 
decreased fusion rate due to Parkin-mediated degradation of mitofusin promotes mitophagy 
(see 2.4 for further detail). On the other hand, mitochondrial elongation interferes with 
mitophagy [107-109]. Decreased translocation of Drp1 to mitochondria has been identified 
during starvation, resulting in a lower rate of fission pushing the balance towards fusion, 
therefore protecting mitochondria from excessive starvation induced mitophagy [110]. 
Besides the maintenance of mitochondrial function, mitochondrial dynamics is also involved in 
the initiation of programmed cell death or apoptosis. The release of cytochrome c from the 
mitochondrial intermembrane space into the cytosol is one of the key steps of the intrinsic 
apoptotic pathway [111], as cytosolic cytochrome c is an essential component of the 
apoptosome involved in caspase activation. Cytochrome c is released as result of mitochondrial 
outer membrane permeabilization (MOMP) induced by pro-apoptotic members of the Bcl-2 
family, e.g. Bax and Bak.  Morphological analyses showed that increased mitochondrial fission 
and fragmentation occurs closely before or during cytochrome c release and the induction of 
apoptosis [112]. Furthermore, Drp1 and Bax translocation to mitochondria are connected, 
further supporting the relationship between mitochondrial fission and apoptosis [113, 114]. 
Interestingly, inhibition of mitochondrial fission interferes with cytochrome c release and slows-
down the induction of apoptosis [115, 116] while excessive mitochondrial fragmentation as a 
result of insufficient mitochondrial fusion is promoting cytochrome c release and, thus, 
apoptosis.  
2.3 The mitochondria associated ubiquitin-proteasome system 
The degradation of damaged or superfluous proteins through proteolytic processes is the most 
critical mechanism for maintaining of cellular protein homeostasis. The most important protein 
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quality control mechanism is the ubiquitin-proteasome system (UPS) as it is responsible for 
targeted degradations of proteins residing in nucleus, the cytosol, and endoplasmic reticulum 
[117] and, as recent evidence suggests, the mitochondria [118].  
2.3.1 The ubiquitin-proteasome system 
The ubiquitin-proteasome system (UPS) is a highly specific proteolytic machinery existing in 
eukaryotic cells whereby the small protein-modifier ubiquitin is transferred to a substrate 
protein destined for degradation by the large, cytosolic proteasome. The UPS is commonly 
recognized as the major route of intracellular proteostasis, where the unfolded, misfolded, or 
abnormally aggregated proteins are selectively targeted and degraded.  
Ubiquitylation is a post-translational protein modification, which requires three enzymatic 
activities to work in concert. The highly conserved ubiquitin protein is in a first step activated by 
the ubiquitin-activating-enzyme (E1), then transferred to one of about 80 ubiquitin-
conjugating-enzymes (E2), until in a third step, ubiquitin is transferred to the substrate protein 
via a so called E3 enzyme or ubiquitin-ligase  [119, 120]. The specificity of this process is 
guaranteed by the many hundreds of distinct ubiquitin-ligases that can recognize particular 
substrates. There are two main classes of E3 ligases classified according to the catalytic domains 
they contain: HECT domain enzymes and RING-finger domain enzymes. HETC domain 
(Homologous to the E6AP C-Terminus) E3 ligases generate Ub-thiolester-intermediate  prior to 
establishing an isopeptidic bond between the C-terminus of Ub and an amino group on the 
substrate protein, while RING-finger E3 ligases catalyze the transfer of activated Ub directly 
from E2 to the substrate [121, 122]. Multiple repetitions of this process, through ubiquitylation 
of ubiquitin itself on lysine residues 48 (Lys48), will elongate the polyUb tails (to least four Ub 
molecules) on the target protein. Upon formation of a polyUb chain on the substrate, 
recognition and degradation of the ubiquitylated substrate protein by the 26S proteasome 
ensues. Besides the well-known Lys48-linked polyubiquitylation, other forms of 
polyubiquitylation occur and impact a diverse array of cellular functions [123] (Figure 2.4). 
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Figure 2.4 Ubiquitin proteasome system (UPS) 
The ubiquitin-activating-enzyme (E1) activates ubiquitin (Ub), transfers it to an ubiquitin-conjugating-enzyme (E2) 
before final transfer of activated ubiquitin with the help of an ubiquitin-ligase (E3) occurs. Due to catalytic domain 
difference, E3 are categorized into HETC domain (Homologous to the E6AP C-Terminus) E3 and RING-finger (Really 
interested new gene) E3. Poly-ubiquitylated proteins are recognized and degraded by the 26S proteasome. As part 
of the proteasomal degradation process deubiquitylation enyzmes (DUB) will release Ub for reuse.  
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2.3.1.1 UPS and organellar protein quality control 
The UPS plays an important role not only in cytosolic proteins turnover, but is also essential for 
organellar proteostasis. The endoplasmic reticulum (ER) is the organelle that proteins pass 
through before entering the Golgi, the plasma membrane, or vacuoles. As part of the quality 
control mechanism called ER-associated degradation or ERAD, abnormal and misfolded proteins 
in the ER are ubiquitylated and retro-translocated to the cytosol for degradation by the 
proteasome [117]. In addition to dedicated E2 and E3 enzymes, ERAD employs different co-
factors to achieve cytosolic protein degradation.  As the substrate proteins originate from a 
membrane confined organelle, additional factors such as the AAA-ATPase Cdc48/p97 are 
required for extraction from the ER (more details discussed later). 
Similar to the ER, mitochondria were recently linked to UPS in form of outer mitochondrial 
membrane-associated degradation or OMMAD [124]. Evidence showed that proteasome 
inhibitors can increase the levels of ubiquitylated mitochondrial proteins, indicating the 
potential role that proteasome plays on mitochondrial protein degradation. Additionally, outer 
mitochondrial membrane proteins such as Mfn1, Mfn2 and Mcl-1 were found to be poly-
ubiquitinated and degraded by the proteasome. Also, several specific E3 ligases were found to 
localize to the OMM and were shown to be involved in the ubiquitylation of mitochondrial 
proteins, including MULAN, Parkin, MARCH5, RNF185, and IBRDC2[15, 125, 126]. Among many 
others, RING-E3 ligases Parkin, MULAN and MARCH5 are widely studied together with their 
potential mitochondrial substrates (mitofusins, Drp1, Mutated SOD1, etc), while the latter one 
is part of our research subjects [27] (Tab. 2.1).  Interestingly and analogous to ERAD, p97 is also 
involved in promoting the extraction of PolyUb-proteins from the mitochondrial membrane and 
transport to the cytosolic proteasome [14]. Previous research has proved that mutated 
mitochondrial proteins like mtSOD1 are selectively degraded through UPS, which support the 
connections between UPS and mitochondrial membrane protein QC directly [19]. Described by 
many studies, several mitochondrial dynamics regulators (mitofusins, Drp1) are involved in 
ubiquitylation processes [127]. Thus, by affecting mitochondrial fission and fusion machinery 
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functions, the UPS is certainly connected to mitochondrial dynamics, therefore participating in 
mitochondrial maintenance. The UPS is also through the ubiquitin E3 ligase Parkin, which serves 
to initiate mitophagy, connected to mitophagic  QC [128].  
Table 2.1 Mitochondrial E3 ligases and known substrates 
Mitochondrial E3 Ligase Localization Mitochondrial Substrates 
Parkin (Ub) Cytoplasm→Mitochondria Mcl-1, Mfn1/2, Drp1 
MULAN (Ub) or 
MAPL (SUMO) 
Mitochondria 
Mitochondria 
Omi/HtrA2 ? 
Drp1 
MARCH5 (Ub) Mitochondria Drp1, Mfn1/2, MuSOD1, 
ataxin-3, polyQ 
IBRDC2 Cytosol and 
Mitochondria 
Bax 
 
Abbreviations:  
MULAN: Mitochondrial Ubiquitin Ligase Activator of NF-kB, MARCH5: membrane-associated RING-CH 5, MAPL: 
mitochondrial-anchored protein ligase, Mcl-1: induced myeloid leukemia cell differentiation protein, Mfn: 
mitofusin, Drp1: dynamin-related protein 1, Omi/HtrA2: Serine protease HTRA2-mitochondrial, SOD: superoxide 
dismutase, PolyQ: Polyglutamine. 
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Figure 2.5 Outer mitochondrial membrane associated degradation 
Outer mitochondrial membrane associated degradation or OMMAD refers to the protein quality control machinery 
localized on the outer mitochondrial membrane, in which multiple ubiquitin ligases namely MARCH5, IBRDC2, 
RNF185, MULAN/MAPL and Parkin are involved. The influence of OMMAD is not only restricted to protein quality 
control, regulation of other mitochondrial functions is connected to this process. Abbreviations: IMM: inner 
mitochondrial membrane, MARCH5: membrane-associated RING-CH 5, MAPL: mitochondrial-anchored protein 
ligase, Mfn: mitofusin, Drp1: dynamin-related protein 1, mtSOD: mutated superoxide dismutase, PolyQ: 
polyglutamate. 
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2.3.2 MARCH5 and mitochondrial quality control 
Membrane-associated ring finger-CH 5 (MARCH5) is an RING-domain ubiquitin E3 ligase found 
to localized to the OMM and to have a regulatory role in  mitochondrial morphology and 
function [129]. Structure analysis demonstrated that MARCH5 is a protein of 278 amino acids, 
containing one short N-terminal Really Interesting New Gene (RING) finger domain and 4 C-
terminal transmembrane domains. Previous work showed that loss of function of RING-domain 
MARCH5 by either point mutation (MARCH5H43W) or RNAi interfering resulted in mitochondrial 
morphology alternations, characterized by excessive interconnected and elongated 
mitochondria [16]. Further experiments demonstrated that MARCH5 affects mitochondrial 
morphology via influencing the docking of Drp1 to prospective mitochondrial fission sites. 
Additionally, MARCH5 was shown to ubiquitylate Drp1 localized on outer mitochondrial 
membrane leading to Drp1 degradation by proteasome [16]. Also, MARCH5 was described to 
be involved in Mnf1 degradation and related mitochondrial functions [130]. Considering the 
mutual expression of Mfn2 on both mitochondria and ER, MARCH5 has also been demonstrated 
to control the intracellular tethering between those two organelles via activating Mnf2 with 
ubiquitin modification [131]. Thus, ER-mitochondrial crosstalk is connected to MARCH5-
dependent mechanisms. Beside mitochondrial dynamics, MARCH5 plays an essential role in 
mitochondrial protein QC. MARCH5 was shown to be involved in the removal of mutated or 
otherwise abnormal proteins, such as ataxin-3-polyQ, or mutated SOD1, through ubiquitylation 
and UPS degradation [19, 20].  Both of them are the cause of two neurodegenerative disorders, 
Machado-Joseph disease and amyotrophic lateral scleroses (ALS), respectively.  
2.3.3 P97/VCP/Cdc48 
Valosin-containing protein (VCP) or p97 in mammals, or CDC48 in yeast and Caenorhabditis 
elegans is a 92kDa protein, which is a well conserved chaperone belonging to AAA (ATPases 
associated with diverse cellular activities) -ATPase family of proteins [23]. In eukaryotic cells, 
p97 accounts for approximately 1% of the total protein content. Studies have confirmed the 
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role of p97 in molecular level of protein quality control as a 'molecular gearbox' and 
'segregation machinery' in ubiquitin proteasome pathway, especially in endoplasmic reticulum 
associated protein degradation (ERAD) [132, 133]. Besides these functions, a variety of cellular 
processes is impacted by p97 function, including transcriptional and metabolic regulation, DNA 
damage response, chromatin remodeling, selective autophagy, cell cycle progression as well as 
cell death [22, 134-136]. 
P97 is a homo-hexameric complex whereby the six subunits are arranged into a ring-like 
structure with a central pore. Each subunit of p97 contains a mobile N-terminal domain and 
two conserved AAA-ATPase domains on the C-terminus, named D1 and D2 [137]. Therefore, the 
p97 complex contains 12 AAA-ATPase in total. However, these ATPase domains are not equival 
in function. The D2 domains play the major activity of p97 in physiological environment, 
whereas D1 is a heat-activated ATPase with a maximum activity at 60 °C. D1 is considered to be 
involved in hexamerization and probably contributes to p97 functioning under heat shock 
conditions [138]. Several co-factors are involved in the many functions of p97. These co-factors 
can be categorized into substrate-recruiting factors and substrates-processing factors, providing 
binding specificity and substrate recognition to p97 complexes [139]. These co-factors contain 
protein-protein interaction motifs including N-domain-interacting UBX domain, UBX-like 
domain, SHP box, VCP-binding motif, and VCP interacting motif (VIM), as well as PUB, PUL 
domains [140-142]. During ERAD, p97 interacts with its co-factors Ufd1 and Npl4, forming a 
p97-Ufd1-Npl4 complex [143, 144]. The resulting complex recognizes and binds to ubiquitylated 
ER membrane proteins, subsequently segregates them from the ER and helps with their 
translocation, and together with additional downstream factors (eg. Dsk2, Rad23) guides 
substrate proteins toward proteasome for degradation [139]. Recently, p97 was connected to 
mitochondrial protein degradation during stress conditions in budding yeast. Here, VCP/Cdc48-
associated mitochondrial stress-responsive protein 1 (Vms1) was shown to participate in p97-
dependent mitochondrial maintenance [145]. In yeast, a Cdc48-Vms1-Npl4 complex specifically 
is established under mitochondrial stress, followed by the degradation of yeast mitofusin Fzo1 
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(yeast Mfn1/Mfn2 ortholog) which had been marked by ubiquitylation [146]. In another 
connection between p97 and mitochondria, Parkin-dependent degradation of mitofusion was 
shown to be p97-depended. Also, mutation of p97 is connected to hereditary inclusion body 
myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD), a 
severe degenerative disorder [147, 148]. IBMPFD was found to be accompanied by impaired 
ERAD, mitochondrial dysfunction, and formation of ubiquitin-tagged protein aggregates [149]. 
These examples support the notion that p97 plays important roles in mitochondrial physiology 
[27]. 
2.3.4 Maintaining mitochondrial function 
2.3.4.1 Levels of mitochondria maintenance / quality control 
Based on the high volume of biochemical processes involving oxygen in mitochondria, the 
complexity and diversity of mitochondrial structure and components is under constant threat. 
Various harmful molecules with the potential to damage mitochondrial components are 
produced during mitochondrial metabolism, as redox reactions inside the electron transport 
chain are the main source of free radicals and ROS generation, such as superoxide anion (O2∙-) 
[150]. Generally, the deleterious effects of ROS to mitochondrial health are due to damage to 
mtDNA and subsequent accumulation of mutations, oxidation of polyunsaturated fatty acids in 
lipids, and oxidation of amino acids in proteins resulting in the inactivation of specific enzymes 
by oxidative modifications [151, 152]. This mitochondrial damage is likely directly linked to cell 
death and neurodegeneration. There is direct evidence linking ROS to neuronal apoptosis or 
necrosis, as it was shown that excessive amount of ROS exposure is correlated with 
neurodegenerative diseases including Alzheimer's disease with diminished memory capabilities, 
cognitive dysfunction, and motor neuron malfunction [153, 154]. As mitochondrial damage is 
the inevitable result of ROS production and as loss of mitochondrial function has serious 
consequences, mitochondrial quality control mechanisms are in place to eliminate harmful ROS, 
as well as its downstream byproducts and effects, and to maintain mitochondrial functions. 
30 
 
These different molecular mechanisms act on various levels namely, the molecular, organelle 
and cellular level [7, 155, 156]. (Figure 2.6) 
 
 
 
Figure 2.6 Levels of mitochondrial quality control 
Mitochondrial quality control (QC) is a system that mitochondria developed against different levels of stresses, and 
can be categorized into three levels based on the involving mechanisms and the stress severity that is being dealt 
with. Molecular level QC is the front line of mitochondrial defense in which many antioxidants like SODs, 
glutathione peroxidase (GPXs), and other detoxifying enzymes participate. Also proteases and DNA-modifying 
enzymes can be considered as part of the molecular level of mitochondrial maintenance. These deal with 
molecular damage caused by mild stresses, such as mtDNA damage, proteins and lipid oxidations. Along with the 
increased levels of stress, mitochondrial function gets partially impaired. Organelle level QC takes charge to 
preserve mitochondrial functions. This organellar level QC involves processes involving mitochondrial dynamics 
and mitophagic processes, to restore the function of the entire mitochondrial network. However, once stress levels 
are high enough to cause devastating damage beyond the capacity of the molecular and organellar QC to salvage, 
cellular level QC will finally launch the apoptotic program to restrict the damage from spreading beyond the 
individual cells to the tissue level. 
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2.4 Mechanisms of mitochondrial quality control  
2.4.1 Molecular level of mitochondrial quality control 
The activities of the molecular level mitochondrial quality control constitute a rapid response to 
mitochondrial stress. As first line of defense is the mitochondrial antioxidant system in place. 
Consisting of antioxidant enzymes such as superoxide dismutase (SOD) peroxidases and 
catalase, the antioxidant system catalyzes the breakdown of superoxide anion (O2∙-) into 
oxygen (O2) and hydrogen peroxide (H2O2). Afterward, H2O2 is broken down by preoxidases and 
catalase (GPX) into H2O and O2. The importance of the antioxidant defense is underlined by the 
consequences of loss of function of the mitochondrial isozyme SOD2 as experiment showed 
that mice lacking SOD2 die shortly after birth [157]. 
Apart from the ROS scavenging antioxidant system as the first line of defense, several other 
mechanisms exist as second line of mitochondria quality control on the molecular level. 
Efficient DNA repair pathways are found to exist in the mitochondrial matrix, including base 
excision repair, direct reversal and mismatch repair. The dynamic DNA repair system can 
respond effectively to mtDNA damage accumulation [158]. Also, lipases are ready to deal with 
lipid-peroxidation by digesting and repairing oxidized lipids maintaining membrane function 
[159].  
Accumulation of unfolded, misfolded or otherwise damaged proteins disturbs mitochondrial 
proteostasis. Mitochondrial protein homeostasis is maintained by balanced protein turnover or 
protein degradation and novo protein synthesis and import into mitochondria. Unlike for DNA, 
only limited mechanisms are in place to directly repair protein damage. One example is the 
methionine sulfide reductase system, consisting of MsrA and MsrB, which can reduce oxidized 
methionine moieties back to methionine. In humans, MsrA localizes both to the 
cytoplasm/nucleus and to mitochondria [75]. As for misfolded proteins, chaperones, such as 
heat shock protein 70kDa (mtHSP70) and heat shock protein 60kDa (mtHSP60), are able to 
guide the refolding of misfolded proteins into native, correct three-dimension structures [160]. 
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Beyond these very limited protein repair mechanisms, degradation of damaged proteins is the 
main pathway for maintaining mitochondrial proteostasis. Different mitochondrial proteases 
are located in mitochondrial matrix, intermembrane space, and the inner mitochondrial 
membrane. ATP-dependent proteases that belong to the AAA+ super-family are important 
components of mitochondrial protein quality control. Both i-AAA and m-AAA proteases are 
located on inner mitochondrial membrane, but oriented oppositely towards the 
intermembrane space or the matrix, respectively [161]. These proteases maintain the electron 
transport chain through their chaperone and protease functions. The function of i-AAA and m-
AAA appears to be vital for mitochondrial biogenesis and maintenance as several hereditary 
neurodegenerative diseases among them spastic paraplegias are connected to mutations in 
these proteases [162]. Also, two AAA+ serine proteases, ClpXP and Lon, exist in the 
mitochondrial matrix, both of which play important roles in soluble matrix protein maintenance 
[163, 164]. 
Besides these specialized mitochondrial proteases, recent evidence has shown that also the 
ubiquitin-proteasome system is involved in mitochondrial membrane protein quality control 
[14]. Several ubiquitin ligases have been discovered localizing on or in association with the  
outer mitochondrial membrane, namely mitochondrial ubiquitin ligase activator of NF-κB 
(MULAN), Parkin, RNF185 [125] in between-RING finger domain protein (IBRDC2) [126] and 
MARCH5 [118]. Similar to endoplasmic reticulum (ER) associate degradation, outer 
mitochondrial membrane associated degradation (OMMAD) is named for mitochondrial protein 
quality control [124]. (Please see 2.3 for a more in-depth description of the UPS and its 
involvement in mitochondrial quality control) 
2.4.2 Organelle level of mitochondrial quality control 
In case of moderate insults causing damage to mitochondria, which cannot reversed on the 
molecular level, mechanisms relying on the dynamic nature of the organelles are taking over. 
Mitochondrial fusion process governed by Mfn1/2 and OPA1, can support the 
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complementation of impaired mitochondrial functions by promoting the mixture of 
mitochondrial contents, thus diluting damaged components below a damage-inducing 
threshold [165]. But also mitochondrial fission is involved in quality control. In contrast to 
fusion, mitochondrial fission is independent of the mitochondrial potential, causing the 
segregation of depolarized mitochondrial subunits by the fission process from the 
mitochondrial network either to be recovered  or turned over by mitophagy [166].  
Mitophagy is a specialized type of organelle autophagy, by which depolarized mitochondrial 
subunits beyond repair are selectively tagged, isolated and expelled from an otherwise healthy 
mitochondrial network, engulfed by autophagosomes and subsequently digested in the 
lysosomal compartment [167]. Mechanisms of mitophagy in mammalian cells have not yet 
been fully elaborated. During the past years, specific mitophagic mechanisms have been 
identified: First of all, the process of erythrocyte maturation from reticulocyte is accompanied 
by the elimination of all intracellular organelles, including mitochondria. Crucial for this 
mitophagy process are the mitochondria outer membrane protein Nix and the microtubule-
associated protein light chain 3 (LC3), both of which are principle autophagosome-associated 
proteins [168]. Another mitophagy mechanism deals with damaged mitochondria and is under 
the control of two Parkinson’s disease related genes: PINK1 (PTEN-induced putative protein 
kinase 1) and Parkin [169]. PINK1 and Parkin were identified through genetic studies connecting 
loss-of-functional mutations in cases of early onset familial Parkinson's disease (PD) [170]. 
PINK1 is a serine/threonine kinase containing a mitochondrial targeting sequence, while Parkin 
is an E3 ubiquitin ligase [171]. Studies in Drosophila showed loss-of-function of both PINK1 and 
Parkin result in similar defects of mitochondria [172, 173]. On polarized, and thus functional, 
mitochondria, PINK1 levels on the outer mitochondrial membrane are low, due to the 
continuous internalization of PINK1 and further cleavage by inner membrane presenilin-
associated rhomboid-like protease (PARL) and mitochondrial-processing protease (MPP) [174, 
175]. However, upon the collapse of the mitochondrial membrane potential due to excessive 
mitochondrial damage, PINK1 internalization and degradation is interrupted resulting in its fast 
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accumulation on the outer mitochondrial surface. In turn, PINK1 acts as a recruiter for Parkin 
from the cytosol to mitochondria, which as the acts as ubiquitin E3 ligase and ubiquitylates 
numerous outer mitochondrial membrane proteins [176]. As result, the docking site for 
ubiquitin-binding adaptor SQSTM1/p62 is established, which accumulates on mitochondria and 
facilitates the recruitment of damaged mitochondrial to autophagosome by binding to LC3 
[177]. Upon Parkin translocation, phosphorylated-Mfn2 might be the potential receptor of 
Parkin to stabilize it on OMM [178]. Based on its E3 ligase activity, the translocation of Parkin 
increases the ubiquitylation status of OMM-localized proteins, many of which are considered as 
substrates of Parkin. For example, the mitofusins Mfn1 and Mfn2 were identified as Parkin 
substrate. Ubiquitylation of mitofusins by Parkin results in their degradtion by the proteasome 
and subsequently inhibits mitochondrial fusion to favor the uneven segregation of depolarized 
mitochondria from healthy ones [179]. Apart from Mfn1/2, many other Parkin substrates have 
been identified, including voltage-dependent anion channel (VDAC), translocase of the OMM 
(TOM) complex (TOM70, TOM40, and TOM20), pro-apoptotic factor Bax, and other[180]. Also, 
ubiquitylated OMM proteins seem to serve as a signal facilitating autophagosome formation 
[181].  
Taken together, mitophagy as organellar level of mitochondrial quality control helps cells to 
selectively eliminate and recycle damaged and uncoupled mitochondria that are beyond repair, 
while preserving healthy mitochondria functioning above a certain threshold, consequently 
preventing further damage leading to cell death. However, the existence of PINK1/Parkin 
mitophagy mechanism in neuron is plausible although the treatment of CCCP induces the 
Parkin translocation in neuron mitochondria [182]. Given the fact that neurons cannot survive 
on exclusive glycolytic metabolism, equally means that they cannot afford with the completely 
loss of mitochondria. As such we hypothesize that limited mitochondria quality control might 
take place in neurons, in order to establish a relatively steady metabolic environment, by the 
ways of selective degradation of unwanted protein or organelles instead of whole organelle 
recycling in a short term [183].  
35 
 
 
 
36 
 
Figure 2.7 Mechanisms of mitochondrial quality control 
Although mitochondrial QC can be categorized into three different levels as described in figure 4, there is no clear 
boundary between them. For mitochondrial QC, molecular, organellar, and cellular mechanisms work together to 
maintain sufficient mitochondrial functions and perusing cellular survival. Abbreviations: ROS: reactive oxygen 
species, SOD2: superoxide dismutase-2, GPX: glutathione peroxidase, TCA: tricaroboxylic acid cycle, i/m-AAA: 
intermembrane space/matrix-ATPase associated with various cellular activities, MULAN: mitochondrial ubiquitin 
ligase activator of NF-kB, MARCH5: membrane-associated RING-CH 5, PINK: PTEN-induced putative kinase, Ub: 
ubiquitin, VDAC: voltage dependent anion channel, Mfn: mitofusin, OPA1: optic atrophy type 1, Drp1: dynamin-
related protein 1, Apaf-1: Apoptotic protease activating factor 1.    
 
2.4.3 Cellular level of mitochondrial quality control 
Above a certain stress level, molecular and organellar QC mechanisms are overwhelmed and 
are no longer able to repair or contain mitochondrial damage. As mitochondrial impairment 
accumulates to a certain level where neither the existing repair systems can sufficiently 
preserve mitochondrial function, putting the mitochondrial network beyond rescue. At this 
point the cellular level of quality control takes effect and commits the entire mitochondrial 
network and therefore the corresponding to apoptosis. One of the first steps in this process is 
the translocation of the fission molecule Drp1 and the pro-apoptotic factor Bax to the outer 
mitochondrial membrane, simultaneously inducing extensive mitochondrial fragmentation 
paired with membrane depolarization and opening of the mitochondrial membrane 
permeability pore, through which cytochrome c is released from the intermembrance space 
into the cytosol [184]. There, cytochrome c interacts with cytosolic Apaf-1 and caspase-9 to 
establish the apoptosome leading to the activation of caspase-3, thus irreversibly starting the 
intrinsic caspase cascade and leading to apoptotic cell death. Apoptosis is considered to be the 
last line of defense against mitochondrial damage to eliminate the threats that possess 
mitochondrial dysfunction to the whole organism [185].  
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2.5 Mitochondria and neurodegeneration  
2.5.1 Neurodegeneration 
Neurodegeneration describes the loss of neuronal cells that accompanies degenerative 
neurological disorders, as the fundamental feature of these disorders is the gradual loss of 
selective neuron resulting in the progressive decline of cognitive and/or motor function. Typical 
examples of neurodegenerative diseases include Alzheimer's disease (AD), Parkinson's disease 
(PD), Amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [186] 
Many important triggers and risk factors are linked to neurodegenerative diseases and the 
associated neuronal cell death. Genetic predisposition as well as genetic mutations are 
considered as one of the main risks for the development of neurodegeneration [187, 188]. For 
example, loss of function mutations in PTEN-induced putative kinase 1 (PINK1) or Parkin were 
identified as causative for familial PD [189]. Furthermore, mutations in the β-amyloid (Aβ) 
precursor protein cause AD [190] or mutations in microtubule-associated protein Tau are the 
reason for frontotemporal dementia (FTD) with Parkinson symptoms [191]. In another example, 
mutations in SOD1 are one of the frequent reasons for familial ALS [192]. Also, protein 
misfolding and abnormal aggregation is observed in many neurodegenerative diseases, 
whether these changes in protein behavior are either cause or consequence is still 
controversial, but they definitely contribute to the vicious circle of neurodegeneration [193, 
194].  For example, hyperphosphorylated Tau protein is the main component of neurofibrillary 
tangles in AD brain biopsy samples [195]; while accumulation of Aβ aggregates is responsible 
for the senile plaques; and α-synuclein can aggregate to form pathological Lewy bodies 
connected to cases of familial AD [196]. It is assumed that abnormal proteins accumulations can 
induce neuronal loss and further neuronal network dysfunction. On the other hand, strategies 
that reduce the production, enhance the elimination, or assist the neutralization of abnormal 
proteins have been shown to counteract neurological disabilities effectively [197].  
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2.5.2 Mitochondrial dysfunction and neurodegeneration 
Neuronal cells have a high energy demand. The brain consumes at nearly 2% of body mass on 
average 20% of the total energy of the body. This makes the neuronal cells almost entirely 
dependent on glucose oxidation for ATP production [198]. Thus, a proper functional 
mitochondrial network with sufficient and persistent ATP production is essential to neuronal 
survival and function. Additionally, highly dynamic calcium fluctuations are happening inside 
neuronal, which also require the steady buffering capacity of mitochondria for calcium ions. 
Despite of the heterogeneous feature of neurodegenerative diseases, the overwhelming 
consensus is that mitochondria are at the heart of neurodegeneration. 
Many neurodegenerative disorders are age related, which is also the most important risk 
factors for such diseases like AD, PD, and ALS. And interestingly, mitochondrial function 
declines with aging. It is assumed that mitochondria accumulate mtDNA mutations and, thus, 
non-functional proteins during the lifespan of the organism, thus contributing to the process of 
aging as well as neurodegeneration due to insufficient ATP production. In addition, 
mitochondria are the trigger of intracellular apoptosis responsible for the final loss of neuron 
cell numbers [199, 200]. Also, extensive literature point at oxidative stress as the key 
perpetrator for neurodegeneration further linking mitochondria to the demise of neurons as 
the main source of ROS [201]. As oxidative stress causes mitochondrial dysfunction and as 
failing mitochondria producing even more ROS [202], a vicious cycle progresses in which more 
oxidative stress induces more structural and metabolic damages (nucleic acid breakdown, 
enzymatic proteins inactivation, lipid peroxidation), resulting in even more severe 
mitochondrial dysfunctions (ATP synthesis impairment, mitochondrial fragmentation, 
mitochondrial membrane depolarization, etc.). [203]. 
Aside the more general concept of oxidative stress and age-related mitochondrial dysfunction 
leading to neurodegeneration, additional links between mitochondrial maintenance or 
dysfunction and neurodegeneration are described. It was shown that around 60% of cases of 
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autosomal dominant optic atrophy (ADOA) are caused by a loss of function mutation of OPA1, a 
known key regulator of mitochondrial inner membrane fusion. Due to impaired mitochondrial 
fusion caused by OPA1 insufficiency, ADOA displays gradually vision loss up to completely 
blindness as result of irreversible retinal ganglion cell damage [84]. In another example, 
Charcot-Marie-Tooth disease 2A (CMT2A) is a heredity autosomal dominant disease 
characterized by primary axonal peripheral neuropathy, sometimes associated with visual and 
hearing impairment. It was shown that mutations of the mitofusin Mfn2 are causative for the 
disease [204]. This is likely due to mitochondrial fusion deficiency caused by Mfn2. However, 
detailed mechanistic insight is still missing, but ADOA and CMT2A strongly link unbalanced 
mitochondrial dynamics to neurodegenerative processes. 
Beyond mitochondrial dynamics, dysfunction of mitochondrial protein degradation is also 
directly linked to neurodegeneration. Multiple studies have investigated the function of 
MARCH5 in mitochondrial protein degradation, and the possible connection to 
neurodegeneration. The degradation of at least three different mitochondrial proteins relies on 
the E3 ligase activity of MARCH5. MARCH5 is able to ubiquitylate mutant SOD1 on mitochondria 
and attenuate the corresponded mitochondria dysfunction. As SOD1 mutation is one of the 
main causes of human ALS [19], MARCH5 function is directly linked to this neurodegenerative 
disease. Further, MARCH5 is responsible for the degradation of mitochondria-localized polyQ 
aggregation in an ubiquitin-proteasome dependent manner, and as previous studies indicated 
that PolyQ toxicity leads to mitochondrial dysfunction and consequently polyQ diseases, 
including Machado–Joseph disease, Huntington's disease or several types of spinocerebellar 
ataxias [20]. And recently the research on MARCH5 demonstrated that it is involved in the 
degradation of NO-stressed mitochondrial protein S-nitrosylated microtubule-associated 
protein 1B-light chain 1 (LC1), and prevented the neuron cytotoxicity [205]. LC1 S-nitrosylation 
has been implicated with several human neurological disorders, such as giant axonal 
neuropathy, fragile-X syndrome, spinocerebellar ataxia type 1, and Parkinson disease [205]. 
Another example is hereditary spastic paraplegia, a human axonal degeneration caused by one 
40 
 
m-AAA protease (paraplegin) mutation. The sufficient function of paraplegin is critical for inner 
mitochondrial membrane proteostasis, especially responsible for the surveillance of proper 
status of electron transport chain complexes which directly links to mitochondrial energy 
production [206, 207].  
In summary, mitochondria are central to cellular survival due to their many different functions.  
Neuron cells, characterized by their high energy demand, distinct metabolic style and long life 
span, are extremely sensitive to mitochondrial insufficiency. Therefore, properly functioning 
mitochondrial maintenance preserving mitochondrial function at high fidelity are essential for 
neuronal health and survival, as the failure of mitochondrial quality control leads to such 
irreversible neurodegeneration. 
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3.1 Abstract 
Purpose: To study the impact of the mitochondrial ubiquitin ligase MARCH5 on mitochondrial 
morphology and induction of apoptosis using an in vitro model of neuronal precursor cells 
exposed to glaucoma-relevant stress conditions.  
Methods: RGC5 cells transfected with expression constructs for MARCH5, MARCH5H43W, 
Dpr1K38A or vector control were exposed to either elevated pressure of 30 mmHg, oxidative 
stress caused by mitochondrial electron transport chain (ETC) inhibition, or hypoxia-
reoxygenation conditions. Mitochondrial morphology of RGC5 cells was analyzed following 
staining of the mitochondrial marker cytochrome c and photoactivatable GFP (PAGFP) diffusion 
assay. Induction of apoptotic cell death in these cells was determined by analyzing the release 
of cytochrome c from mitochondria into the cytosol and flow cytometry. 
Results: Exposure of RGC5 cells to oxidative stress conditions as well as to elevated pressure 
resulted in the fragmentation of the mitochondrial network in control cells as well as in cells 
expressing MARCH5. In cells expressing inactive MARCH5H43W or inactive DrpK38A, mitochondrial 
fragmentation was significantly blocked and mitochondrial morphology was comparable to that 
of control cells under normal conditions. Exposure of RGC5 cells to elevated pressure or 
oxidative stress conditions induced apoptotic cell death as assessed by cytochrome c release 
and DNA staining, while expression of dominant-negative MARCH5H43W or Drp1K38A did 
significantly delay cell death. 
Conclusion: Preventing mitochondrial fragmentation through interference with the 
mitochondrial fission machinery protects neuronal cells from programmed cell death following 
exposure to stressors physiologically relevant to the pathogenesis of glaucoma. 
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3.2 Background 
Death of retinal ganglion cells (RGCs) is responsible for vision loss in glaucoma patients. The 
exact mechanisms causing the demise of RGCs are still under investigation. Different triggers in 
the various forms of glaucoma probably lead to the observed neurodegenerative process. 
Elevated intraocular pressure (IOP) is involved in RGC death associated with high-tension 
glaucoma (HTG) [1], while vascular dysregulation and associated ischemia-reperfusion injury is 
linked to normal-tension glaucoma (NTG) [2]. Irrespective of the actual trigger and the 
glaucoma subtype, at its heart, glaucoma is a slowly progressing neurodegenerative disorder. 
RGC5 cells were used as cellular model. These cells are murine neuronal precursor cells and 
display certain features such as the expression of specific neuronal marker upon differentiation 
with various compounds [3]. 
As mitochondrial dysfunction is generally accepted to be one unifying theme for all 
neurodegenerative disorders [4], mitochondria and failing mitochondrial function connect the 
different glaucoma subtypes. Due to the complex architecture of mitochondria and their 
endosymbiotic origin [5], diverse systems are in place to maintain mitochondrial fidelity [6]. 
These systems include bacterial type proteases dealing with oxidatively damaged mitochondrial 
matrix proteins, but also inner mitochondrial membrane-anchored proteases involved in 
protein processing and protein degradation. Recently, we and others described an important 
role for the ubiquitin-proteasome system (UPS) and ubiquitin-dependent protein degradation 
in mitochondrial maintenance [7]. Membrane-anchored ubiquitin ligases such as MULAN/MAPL 
[8-9], RNF185 [10] and MITOL/MARCH5 [11-13] were shown to impact mitochondrial 
physiology. Furthermore, MARCH5 was demonstrated to promote the degradation of mSOD1 
[14], a protein linked to amyotrophic lateral sclerosis, and of polyQ-extended ataxin-3 causative 
for Machado-Joseph disease [15]. In addition, MARCH5 was connected to the degradation of 
nitrosylated proteins suggesting a role for this ubiquitin ligase in mitochondrial quality control 
[16]. Besides the degradation of damaged or superfluous proteins, mitochondrial maintenance 
critically depends on balanced mitochondrial morphology. Mitochondria form a dynamic 
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network constantly reshaped by the fission and fusion of mitochondrial tubules [17]. MARCH5 
was implicated by us and others in the regulation of mitochondrial morphology with 
inactivation of MARCH5 causing massive mitochondrial elongation due to a block in 
mitochondrial fission [12]. Mitochondrial fusion is mediated by the mitofusins Mfn1 and Mfn2 
that together with Opa1 perform the coordinated fusion of outer and inner mitochondrial 
membranes. Interestingly, mutations in fusion components are linked to neurodegenerative 
disorders with Opa1 mutations causative for dominant optic atrophy [18] and mutations in 
Mfn2 linked to Charcot-Marie-Tooth type 2A disease, a peripheral neuropathy sometimes 
accompanied by optic degeneration and hearing loss [19]. Division of mitochondria is 
performed by the dynamin-related protein Drp1 together with hFis1, Mff and MiD49/51[20-22]. 
In a rare case, mutation of Drp1 caused premature death accompanied by microcephaly, 
persistent lactic acidemia as well as optic degeneration [23], strongly pointing to an underlying 
mitochondrial etiology. Thus, dynamically balancing and adapting the organelles morphology is 
an integral part of mitochondrial maintenance and essential for neuronal survival. This is 
especially true for RGCs, most likely due to their highly specialized anatomy involving non-
myelinated parts, their exposure to UV stress, and their - even for neuronal cells - exceptional 
energy demand [1]. This integration of mitochondrial morphogens into cellular physiology is 
mirrored in their connection to programmed cell death [24]. Interference with mitochondrial 
fusion and fission dynamics modulates cell death thresholds with excessive fission sensitizing 
and blocked fission desensitizing cells to apoptotic stimuli [25-26]. Consistent with glaucoma 
being a neurodegenerative disorder and a protective role of mitochondrial fusion in most 
experimental paradigms, increased expression of the OPA1 fusion protein is protective for RGCs 
in a mouse model of glaucomatous nerve damage [27]. 
To investigate the role of the mitochondrial ubiquitin ligase MARCH5 and mitochondrial 
maintenance during neuronal cell stress, we studied mitochondrial dynamics and induction of 
cell death in neuronal cells with altered mitochondrial maintenance under physiologically 
relevant stress conditions. 
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3.3 Results 
Exposure of differentiated RGC5 cells to 30 mmHg elevated pressure for three days, to the 
mitochondrial complex I inhibitor rotenone or to hypoxia-reoxygenation conditions resulted in 
the fragmentation of the mitochondrial network (Figure 3.1). While the mitochondrial network 
in cells kept under ambient pressure displayed normal tubular mitochondrial morphology, in 
about 60 % of cells exposed to elevated pressure mitochondria switched to a fragmented 
phenotype. For oxidative stress conditions, treatment with rotenone resulted in about 80 % of 
RGCs in mitochondrial fragmentation, while reoxygenation was responsible for fragmented 
mitochondria in about 30 % of cells.  
As shown in Figure 3.2, expression of MARCH5 in comparison to control cells did not interfere 
with pressure-induced mitochondrial fragmentation. Interestingly, expression of a RING-
deficient, dominant-negative MARCH5H43W significantly blocked pressure-induced 
mitochondrial fragmentation and was able to maintain normal mitochondrial morphology in 
about 75 % of cells (Figure 3.2A). Measuring mitochondrial interconnectivity using a 
photoactivatable GFP (PAGFP) diffusion assay in cells expressing MARCH5, MARCH5H43W or YFP 
as control confirmed that expression of MARCH5 did not block pressure-induced changes in 
mitochondrial interconnectivity, while inactive MARCH5H43W prevented the pressure-induced 
alteration of the mitochondrial network (Figure 3.2B). To evaluate the specificity of pressure-
induced mitochondrial fragmentation in RGC5 cells, HeLa cells were exposed to identical 
pressure conditions, and no mitochondrial fragmentation was observed (data not shown). 
Blocking of mitochondrial fission through expression of dominant-negative Drp1K38A was used 
to assess the specificity of MARCH5H43W action on mitochondrial morphology following 
exposure to stress conditions. As shown in Figure 2C, mitochondrial fragmentation was not 
blocked in RGC5 cells expressing Drp1 following exposure to elevated pressure, while Drp1K38A 
was capable of blocking organelle fragmentation in about 70 % of cells under these conditions. 
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Figure 3.1: Stress-induced mitochondrial fragmentation in RGC5 cells  
Differentiated RGC5 cells were exposed to 0.25 µM rotenone for 12 hours, 30 mmHg elevated pressure for 72 
hours or hypoxia-reoxygenation (24 hours 1 % oxygen, 2 hours normoxia), fixed and stained using anti-cytochrome 
c antibodies. Mitochondrial morphology was scored visually. Shown are the averages of three independent 
experiments (>200 cell counted/condition) with error bars representing SEM and * representing p<0.05 and ** 
representing p<0.01 (Student’s t-test). 
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Figure 3.2: Inactivation of MARCH5 and Drp1 blocks pressure-induced mitochondrial 
fragmentation.  
(A) Differentiated RGC5 cells transfected with expression constructs for MARCH5YFP or MARCH5H43W-YFP were 
exposed for 72 hours to 30 mmHg elevated pressure or left untreated as control. Mitochondrial morphology was 
assessed following cytochrome c staining. The bar graph represents three independent experiments (>200 cell 
counted/condition) with * marking p<0.05 and ** marking p<0.01 (Student’s t-test). Error bars correspond to SEM. 
(B) RGC5 cells expressing MARCH5 or MARCH5H43W and photoactivatable GFP (PAGFP) were exposed to 30 mmHg 
for three days or left untreated as control and mitochondrial interconnectivity was measured by PAGFP diffusion 
after photoactivation and compared to ambient pressure, MARCH5 expressing cells. Analyzed were 20 
cells/condition with the error bars representing SEM and ** marking p<0.01 and n.s. marking p>0.05 (Student’s t-
test). (C) Differentiated RGC5 cells transfected with expression constructs for Drp1YFP or Drp1K38A-YFP were treated 
as described in A. 
 
In an experimental paradigm of oxidative stress, exposure of differentiated RGC5 cells to 
rotenone, an inhibitor of the complex I of the electron transport chain, did also result in 
mitochondrial fragmentation (Figure 3.3A+B) as compared to untreated control cells. Control 
cells or cells expressing wildtype MARCH5 displayed mitochondrial fragmentation under these 
conditions. However, ectopic expression of MARCH5H43W interfered with rotenone-induced 
mitochondrial fragmentation with almost 60 % of cells maintaining a tubular mitochondrial 
network (Figure 3.3B). Measuring mitochondrial interconnectivity using PAGFP diffusion assay, 
we confirmed the inhibition of rotenone-induced fragmentation of the mitochondrial network 
by inactive MARCH5H43W but not wildtype MARCH5 (Figure 3.3C). Drp1K38A was able to interfere 
with mitochondrial fragmentation in differentiated RGC5 cells under oxidative stress conditions. 
While around 80 % of control or Drp1-expressing cells displayed mitochondrial fragmentation 
following rotenone treatment, mitochondrial morphology was tubular in around 60 % of 
Drp1K38A-expressing cells (Figure 3.3A+B). 
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Figure 3.3: Rotenone-induced mitochondrial fragmentation is reduced following MARCH5 or 
Drp1 inactivation.  
(A + B) Differentiated RGC5 cells expressing MARCH5YFP, MARCH5H43W-YFP, Drp1YFP or Drp1K38A-YFP were exposed to 
0.25 µM rotenone for 12 hours prior to fixation and cytochrome c staining. Shown is the average of three 
independent experiments (>200 cell counted/condition), with ** marking p<0.01 (Student’s t-test) and error bars 
representing SEM. (C) RGC5 cells expressing MARCH5 or MARCH5H43W and PAGFP were exposed to 0.5 µM 
rotenone for 4 hours and mitochondrial interconnectivity was assessed by measuring PAGFP diffusion following 
photoactivation. Analyzed were 20 cells/condition with error bars representing SEM and ** marking p<0.01 and 
n.s. marking p>0.05 (Student’s t-test). 
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Re-oxygenation following exposure to low oxygen atmosphere mimicking ischemia-reperfusion 
conditions induces mitochondrial fragmentation in differentiated RGC5 cells (Figure 3.1 and 
3.4). Re-oxygenation-induced mitochondrial fragmentation was not blocked in cells ectopically 
expressing MARCH5 or Drp1 when compared to transfected control cells (Figure 3.4). 
Interestingly, ectopic expression of MARCH5H43W or Drp1K38A did completely block 
mitochondrial fragmentation under these conditions (Figure 3.4A). We confirmed this 
observation in MARCH5 or MARCH5H43W expressing cells treated with hypoxia-reperfusion using 
PAGFP diffusion assay (Figure 4B).  
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Figure 3.4: Mitochondrial fragmentation following hypoxia-reoxygenation is ameliorated by 
inactivation of MARCH5 or Drp1. 
(A) Differentiated RGC5 cells expressing MARCH5YFP, MARCH5H43W-YFP, Drp1YFP or Drp1K38A-YFP were cultured in the 
presence of low oxygen (1 %) for 24 hours followed by normoxia for 2 hours. Mitochondrial fragmentation was 
analyzed following cytochrome c staining in three independent experiments (>200 cell counted/condition). Error 
bars represent SEM, p-Values for Student’s t-test are marked with * (p<0.05) or ** (p<0.01). (B) RGC5 cells 
expressing MARCH5 or MARCH5H43W and PAGFP were stressed using hypoxia-reoxygenation and mitochondrial 
interconnectivity was assessed by measuring PAGFP diffusion following photoactivation. Analyzed were 20 
cells/condition with error bars representing SEM and ** marking p<0.01 and n.s. marking p>0.05 (Student’s t-test). 
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Furthermore, we assessed whether modulation of mitochondrial morphology through 
expression of Drp1K38A or MARCH5H43W altered the sensitivity of differentiated RGC5 cells to 
apoptotic stimuli. To this end, RGC5 cells were exposed either to 100 mmHg elevated pressure 
for one day, rotenone alone, or a combination of elevated pressure and rotenone, and 
apoptotic induction in the presence of pan-caspase inhibitor was assessed by counting the 
release of cytochrome c from mitochondria. As shown in Figure 5, exposing RGC5 to these 
stress conditions leads to the induction of apoptotic cell death in control cells and in cells 
expressing wildtype MARCH5 (Figure 3.5A) or Drp1 (Figure 3.5B). Interestingly, expression of 
MARCH5H43W (Figure 3.5A) or Dpr1K38A (Figure 3.5B) resulted in significant suppression of 
apoptotic cell death induction. 
To further examine the extent to which inactivation of mitochondrial fission by mutant 
MARCH5 or mutant Drp1 delays apoptosis, we measured cell death following prolonged 
exposure to oxidative stress conditions. To this end, cells expressing MARCH5 or MARCH5H43W 
(Figure 3.5C) or Drp1 or Drp1K38A (Figure 3.5D) or YFP as control were treated for 24 or 48 hours 
with 1 µM rotenone or left untreated. The amount of accumulating dead cells following this 
treatment was measured using flow cytometric analysis of 7-aminoactinomycin D (7-AAD) 
exclusion. Interestingly, expression of wildtype MARCH5 (Figure 3.5C) or wildtype Drp1 did not 
interfere with the progression of cell death, while MARCH5H43W or Drp1K38A did significantly 
diminish cell death during 24 hours of rotenone treatment in comparison to control or MARCH5 
or Drp1 expressing cells, respectively. However, at 48 hours of rotenone treatment, neither 
expression of MARCH5H43W nor Drp1K38A did significantly alter the accumulation of 7-AAD-
positive cells. 
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Figure 3.5: Inactivation of MARCH5 or Drp1 delays induction of apoptosis and cell death.  
RGC5 cells expressing (A) MARCH5YFP, MARCH5H43W-YFP or YFP as control or (B) Drp1YFP or Drp1K38A-YFP or YFP as 
control were exposed to 100 mmHg for 24 hours, 1 µM rotenone for 6 hours or combined 100 mmHg pressure and 
1 µM rotenone in the presence of the pan-caspase inhibitor zVAD-fmk. Following treatment, cells were fixed and 
cytochrome c release from mitochondria into the cytosol was assessed by fluorescence microscopy (>200 cell 
counted/condition). The bar graphs represent four independent experiments with * marking p<0.05 and ** 
marking p<0.01 (Student’s t-test). RGC5 cells expressing (C) MARCH5YFP, MARCH5H43W-YFP or YFP as control or (D) 
Drp1YFP or Drp1K38A-YFP or YFP as control were exposed to 1 µM rotenone for 0, 24 or 48 hours and the amount of 
dead cells was measured by flow cytometry following 7-AAD staining of DNA. 
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3.4 Discussion 
Mitochondrial fidelity is important for neuronal survival, with failing mitochondria and 
mitochondria-mediated cell death involved in neuronal degeneration. Therefore, maintaining 
mitochondria in a healthy and functional state is essential for neuronal survival. Mitochondrial 
surveillance and repair is performed by a multi-tiered system involving specialized 
mitochondrial proteases, the ubiquitin-proteasome system, properly balanced mitochondrial 
dynamics, but also cell death mechanisms [4]. The mitochondrial ubiquitin ligase MARCH5 is 
involved in mitochondrial maintenance through the clearing of mutated, damaged 
mitochondrial proteins but also through regulating mitochondrial fission [12, 14-16]. Both of 
these functions of MARCH5 are important for neuronal survival. Degradation of proteins such 
as mSOD1 or polyQ-ataxin-3 associated with amyotrophic lateral sclerosis or Machado-Joseph 
disease [15], respectively, by MARCH5 was shown to exert neuroprotective functions. 
Furthermore, maintenance of a plastic mitochondrial network through balanced mitochondrial 
fission and fusion was shown to be important for neuronal survival. For example, mfn2-/- mice 
display severe loss of Purkinje cells likely caused by unbalanced mitochondrial dynamics [28]. 
Furthermore, in humans, impaired mitochondrial fusion caused by mutations in Opa1 and Mfn2 
are associated with dominant optic atrophy or Charcot-Marie-Tooth disease 2A (CMT2A), 
respectively. We now identified a role for MARCH5 in the death neuronal cells caused by stress 
conditions that are relevant for glaucoma progression. We found that modulation of 
mitochondrial morphology through MARCH5 depends on its regulation of Drp1 recruitment to 
the OMM. For mitochondrial fission to occur cytosolic Drp1 has to assemble into fission 
complexes on mitochondria in a MARCH5-dependent manner; expression of dominant-negative 
MARCH5H43W locks Drp1 in fission-incompetent mitochondrial division complexes. The observed 
block in mitochondrial fission in differentiated MARCH5H43W-expressing RGC5 cells following 
exposure to elevated pressure, oxidative stress or to ischemia-reperfusion conditions is 
consistent with the known role of MARCH5 in the regulation of mitochondrial morphology [12]. 
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This notion is supported by our findings that expression of dominant-negative Drp1K38A but not 
of wildtype Drp1 blocks mitochondrial fragmentation following elevated pressure, oxidative 
stress or re-oxygenation in a comparable manner. This finding is consistent with MARCH5 acting 
upstream of Drp1 in the regulation of mitochondrial fission. Interestingly, inactivation of 
MARCH5 blocks mitochondrial fragmentation under the tested stress conditions as effectively 
as dominant-negative inactivation of Drp1 function. While the exact role of MARCH5 during 
mitochondrial fission is still unclear, our data suggest a strong dependence of Drp1-mediated 
fission on MARCH5 activity.  
Whereas MARCH5 is neuroprotective under conditions of insufficient protein quality control as 
seen e.g. in Machado-Joseph disease [15], its expression has no beneficial effect under 
glaucoma-relevant stress conditions. In contrast, inactivation of MARCH5 function through 
dominant-negative action of MARCH5H43W exerts anti-apoptotic activity, slows down cell death 
and exerts a neuroprotective function. Thus, under the conditions tested here, the function of 
MARCH5 in mitochondrial division is predominant. In addition, elevated pressure, oxidative 
stress and ischemia-reperfusion do not seem to cause damage to mitochondrial proteins that 
are under the surveillance of the mitochondrial ubiquitin ligase MARCH5. One might speculate 
that inhibition of mitochondrial fragmentation through pharmacological inactivation of 
MARCH5 might be beneficial under certain circumstances, similar to what has been shown for 
Drp1, where pharmacological inhibition of mitochondrial fission by the small molecule Drp1 
inhibitor mdivi-1 proved neuroprotective [29]. 
3.5 Conclusions  
Taken together, the versatile mitochondrial ubiquitin ligase MARCH5 impacts neuronal survival 
in various ways either through the degradation of damaged mitochondrial proteins or by 
modulating mitochondrial morphology. In case of glaucoma-related stressors and neuronal 
cells, the role of MARCH5 as fission regulator outweighs its other roles in maintaining 
mitochondrial proteostasis. 
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3.6 Methods 
3.6.1 Cell culture  
Immortalized neuronal precursor cells (RGC5) were cultured in high glucose DMEM, 
supplemented with 10 % fetal bovine serum, 2mM L-glutamine, MEM non-essential amino acid 
(Sigma-Aldrich) and incubated in a humidified incubator at 5 % CO2 and 37°C. RGC5 cells were 
received as gift from Neville Osborne (University of Oxford) and tested as of mouse origin by 
PCR [30] and are thus considered neuronal precursor cells instead of retinal ganglion cells as 
originally proposed [31]. Where stated, cells were cultured in media containing 1% FBS. For 
immunocytochemistry, cells were seeded onto sterilized 18mm diameter glass coverslips in 6-
well plates at a density of 1x105 cells/well. Cells were transfected using Effectene (Qiagen) at a 
ratio of 1:10 (DNA:transfection reagent) following manufacturer’s instructions. 
To induce differentiation of RGC5 cells, cells were seeded into appropriate vessels and allowed 
to attach for 6h in media containing 10 % FBS before changing to serum-free media for 24 
hours. Afterwards, cells were incubated in FBS medium containing succinyl-concanavalin A 
(50µg/ml) for 3 days [31].  
To expose RGC5 cells to elevated pressure, cells were placed into a custom-made pressure 
chamber [32] and exposed to 30mmHg (72 h) or 100mmHg (24 h) above ambient pressure. To 
induce oxidative stress, RGC5 cells were treated with the mitochondrial complex I inhibitor 
rotenone (Sigma-Aldrich) at the indicated concentrations. To expose RGC5 cells to hypoxia-
reoxygenation, cells were cultured at 1% oxygen/5% CO2 for 24 hours following exposure to 
normoxia for 2 hours prior to fixation. 
To prevent progression of apoptosis following stress treatment, cells were pre-treated with 50 
µM of the pan-caspase inhibitor zVAD-fmk (PeptaNova). 
3.6.2 Immunocytochemistry  
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To assess mitochondrial morphology and release of cytochrome c, RGC5 cells were fixed using 
methanol-free electron microscopy grade 4% paraformaldehyde in PBS (Pierce) for 15 minutes 
at RT, permeabilized for 15 minutes at RT using 0.15 % Trixon X-100 in PBS and blocked for 1 h 
in 10 % BSA in PBS. To stain for cytochrome c, cells were incubated with mouse anti-
cytochrome c antibody (1:1000, Abcam 556432) and Alexa546-conjugated anti-mouse 
antibodies (1:500, Invitrogen). Samples were mounted using mounting medium (Vectashield, H-
1000) and observed using immunofluorescence microscopy (Olympus BX 61, 60x/1.35 
objective) or confocal microscopy (Zeiss Meta710, 63x/1.4 objective). 
3.6.3 Analysis of mitochondrial morphology  
Mitochondrial morphology was judged visually following cytochrome c staining relying on 
observer experience. Mitochondria were judged “normal” if appearance resembled control 
cells with mostly middle sized mitochondria and only some smaller fragments. Mitochondria 
were scored as fragmented if the majority of mitochondria (>90 %) were either round or slightly 
elongated (length < 2x width). Mitochondria were scored as elongated if only a minor fraction 
of mitochondria were of “normal” size and organelle continuously extended across the entire 
length/width of the cell. Each experiment was done independently at least three times and a 
minimum of 200 cells/condition were counted by an unblinded observer. 
To more quantitatively assess mitochondrial morphology, RGC-5 cells were cultured on 
chambered cover glass and co-transfected in a 1:3 ratio with mitochondria-targeted 
photoactivatable GFP (mito-PAGFP) and MARCH5 or MARCH5H43W expression constructs. The 
PAGFP assay was performed on a LSM710 confocal microscope (Zeiss) equipped with a 63x 
objective using ZEN software. For photoactivation, a 75 pixel wide circle was randomly selected. 
Activation was performed using the 405nm laser line (100% output) at zoom 4, 100μs pixel 
dwell time and 2 iterations. One z-stack, both before and after activation, was acquired (5 
images at a 0.67μm interval). LSM Image Browser (Zeiss, v. 4.2.0.121) and ImageJ (NIH, v. 1.45s) 
were used to analyze mitochondrial interconnectivity as follows: the activated area (75 pixels) 
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was masked and a maximum intensity projection of the z-stack was created using LSM Image 
Browser. ImageJ was used to measure the total area of fluorescent mitochondria outside the 
photoactivated area (steps performed in ImageJ: threshold adjustment so that only 
photoactivated mitochondria were visible, then median filter radius 2 followed by analyze 
particles size 25-infinity). Twenty randomly selected cells were analyzed for each condition. The 
measured area was compared between different treatment groups relative to untreated 
MARCH5-expressing cells. 
3.6.4 Flow cytometric analysis of cell death  
RGC5 cells expressing MARCH5YFP, MARCH5H43W-YFP or YFP as control were treated with 1µM 
rotenone for 24 or 48 hours or left untreated. Attached and floating cells were harvested, 
stained with 1µg/ml 7-aminoactinomycin D and analyzed by flow cytometry (CyAn ADP, 
Beckman Coulter). 7-AAD fluorescence (FL4) was measured in YFP positive cells to determine 
percentage of dead cells. 
3.6.5 Statistical analysis  
All experiments were performed at least three times. For each experiment a minimum of 200 
cells/condition were counted. Statistical analysis was done using unpaired, two-tailed Student's 
t-test as implemented in Microsoft Excel. A p-Value of <0.05 or smaller was considered 
statistically significant and is marked with *, while p-Values of <0.01 are marked with **. Error 
bars represent the standard error of the mean (SEM). For PAGFP diffusion assay, 20 cells per 
condition were measured and statistical analysis was performed as described above. 
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4.1 Abstract 
 
Neuronal cell death is accompanied by mitochondrial dysfunction with mitochondrial 
maintenance critical to neuronal survival. The mitochondrial ubiquitin ligase MARCH5 has dual 
roles in the upkeep of mitochondrial function. MARCH5 is involved in targeted degradation of 
proteins harmful to mitochondria and impacts mitochondrial morphology upstream of the 
fission protein Drp1. In a neuronal cell model, dominant-negative MARCH5 prevents 
mitochondrial fragmentation during neurodegenerative stress induced by the neuron-specific 
reactive oxygen generator 6-hydroxydopamine, the complex I inhibitor rotenone or 
Alzheimer’s-releated Aβ peptide. In addition, preservation of mitochondrial function in terms of 
membrane potential and lower reactive oxygen generation was observed following inactivation 
of MARCH5. Our findings connect MARCH5 to neuronal stress responses and further emphasize 
the link between mitochondrial dynamics and function. 
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4.2 Introduction 
Mitochondrial dysfunction is at the heart of neurodegeneration [1], since neuronal cells are 
especially dependent on high fidelity mitochondria to meet their extraordinary energy demand. 
Loss of mitochondrial fidelity due to accumulation of damage is thought to be one of the 
central mechanisms for the death of neuronal cells associated with virtually all 
neurodegenerative disorders as well as aging. Damage to mitochondria is caused mainly 
through reactive reaction intermediates of the mitochondrial electron transport chain (ETC) 
namely reactive oxygen (ROS) and reactive nitrogen species (RNS). Main targets of ROS and RNS 
are mitochondrial proteins as well as mitochondrial DNA but also mitochondrial lipids. 
Especially damage to proteins of the ETC and to mitochondrial DNA, which codes mainly for ETC 
components, impacts mitochondrial health as a subpar ETC gives rise to even more reactive 
intermediates through electron leakage. Various repair, salvage and maintenance mechanisms 
are in place to deal with such stresses and to keep mitochondria in a healthy and functional 
state. On the level of mitochondrial DNA, various repair mechanisms are active, drawing from 
the large redundancy of mitochondrial DNA with up to 10’000 copies per cell [2]. On the protein 
level, removal of damaged proteins takes place via specialized proteases in the matrix and inner 
mitochondrial membrane [3] or through the ubiquitin-proteasome system during outer 
mitochondrial membrane associated degradation (OMMAD) [4]. On the organellar level, the 
mitochondrial network is maintained through dynamic fission and fusion of mitochondrial 
tubules essential for adaption of the network to cellular demand [5]. Furthermore, removal of 
irreparable mitochondrial subunits by mitophagy, a specialized autophagic process, is essential 
for maintaining organellar fidelity [6]. Lastly, on the cellular level, irreparable damage to the 
mitochondrial network causes the induction of apoptosis, thus constituting a complete removal 
of dysfunctional organelles [1, 7]. In the case of neuronal tissue with its very limited capacity for 
regeneration, induction of the cell death program is deleterious and results in the irreparable 
loss of neuronal function leading ultimately to neurodegenerative disease. 
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The mitochondrial ubiquitin ligase MARCH5/MITOL [8, 9] is involved in maintaining 
mitochondrial function. MARCH5 was shown to regulate mitochondrial morphology through 
regulating Drp1 activity [8], thereby impacting cellular senescence [10] and modulating 
neuronal death [11]. Furthermore, MARCH5 was implicated in the regulation of ER-
mitochondrial tethering through ubiquitination of mitofusin Mfn2 [12]. MARCH5 also plays a 
role in the degradation of mSOD1 associated with amyotrophic lateral sclerosis [13], in the 
disposal of mutated ataxin-3 causative for Machado-Joseph disease [14] as well as the 
clearance of S-nitrosylated MAP1B-light chain 1 linked to neuronal degeneration [15]. 
Here we found MARCH5 to be involved in the mitochondrial answer to neurodegenerative 
stress evoked by 6-hydroxydopamine, a superoxide generating compound selective for 
neuronal cells, the mitochondrial poison rotenone or Alzheimer’s related amyloid beta (Aβ). 
While MARCH5 increased mitochondrial effects of neurodegenerative stress, inactivation of 
MARCH5 reversed stress-induced fragmentation and strongly ameliorated stress-related 
mitochondrial dysfunction pointing to an active role of MARCH5 in stress response decisions. 
4.3 Results 
Here, treatment of SH-SY5Y neuroblastoma cells with the dopaminergic and noradrenergic 
neuron-specific ROS generator 6-hydroxydopamine, the mitochondrial ETC complex I inhibitor 
rotenone, or the Aβ peptide was employed to study mitochondrial function in a model for 
neuronal cells under neurodegenerative stress. As revealed by cytochrome c staining, following 
treatment with 6-hydroxydopamine (Figure 4.1 – second panel), rotenone (Figure 4.1A – third 
panel) or Aβ peptide (Figure 4.1 – fourth panel) the mitochondrial network is considerably 
fragmented when compared to control cells (Figure 4.1 – first panel). The extent of 
mitochondrial fragmentation was strongest with 6-hydroxydopamine, still strong following 
rotenone and less pronounced after Aβ treatment. These data are consistent with 
mitochondrial fragmentation in neuronal cells in response to neurodegenerative stress evoked 
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by exogenous ROS, mitochondria-generated ROS as well as mitochondrial dysfunction due to 
Aβ, respectively. 
 
Figure 4.1: Neurodegenerative stress causes mitochondrial fragmentation in neuronal cells.  
SH-SY5Y cells mock treated (control) or exposed for 6 hours to 75 µM 6-hydroxydopamine (6-HODA), for 6 hours to 
5 µM rotenone (rotenone), or for 24 hours to 25 µM Aβ peptide (Aβ) were fixed and stained using anti-cytochrome 
c antibodies and DAPI to reveal mitochondrial morphology and the nucleus, respectively. Shown are representative 
pictures of at least three independent experiments. 
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To study the role of MARCH5 in the mitochondrial response to neurodegenerative stress in 
neuronal cells, wildtype MARCH5, ubiquitin ligase activity negative MARCH5H43W or 
mitochondria-targeted yellow fluorescent protein (mitoYFP) as control were stably expressed in 
SH-SY5Y cells. As shown in Figure 4.2A and consistent with previous observations in HeLa cells 
[8], expression of MARCH5 in SH-SY5Y cells had no discernible impact on mitochondrial 
morphology, while expression of dominant-negative MARCH5H43W caused considerable 
elongation of the mitochondrial network when compared to control cells. In addition and as 
also reported previously [8], MARCH5H43W localized to distinct sub-mitochondrial foci in SH-
SY5Y cells while wildtype MARCH5 localized to mitochondria in a circumscribing fashion.  
To test whether MARCH5 activity is necessary for neurodegenerative stress-induced 
mitochondrial fragmentation, cells stably expressing MARCH5, MARCH5H43W or mitoYFP were 
treated with 6-hydroxydopamine (Figure 4.2B), rotenone (Figure 4.2C) or Aβ (Figure 4.2D) and 
mitochondrial morphology was observed following cytochrome c staining. While mitochondrial 
fragmentation was still evident in cells expressing MARCH5 or YFP, expression of MARCH5H43W 
in SH-SY5Y cells prevented mitochondrial fragmentation evoked by neurodegenerative stress 
conditions. 
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Figure 4.2: Inactivation of MARCH5 prevents stress-induced mitochondrial fragmentation.  
SH-SY5Y cells selected to express mitochondria-targeted YFP (mitoYFP), MARCH5-YFP or MARCH5H43W-YFP mock 
treated (A) or treated with 75 µM 6-hydroxydopamine for 6 hours (B), 5 µM rotenone for 6 hours (C), or 25 µM Aβ 
peptide for 24 hours (D) were fixed and stained using anti-cytochrome c antibodies and imaged using confocal 
microscopy (cytochrome c – red, YFP – green). Shown are representative pictures of at least three independent 
experiments. 
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To quantify the impact of MARCH5H43W on preservation of mitochondrial morphology in SH-
SY5Y cells following neurodegenerative stress, mitochondrial interconnectivity was measured. 
To this end, SH-SY5Y cells co-transfected with expression plasmids for MARCH5 or MARCH5H43W 
and mitochondria-targeted photoactivatable GPF (PA-GFP) were treated with 6-
hydroxydopamine (Figure 4.3A), rotenone (Figure 4.3B) or  Aβ (Figure 3C) or mock treated as 
control and diffusion of PA-GFP was measured following 405 nm laser activation of a small part 
of the mitochondrial network. The area of PA-GFP of the mitochondrial network covered by 
activated PA-GFP served as measure for interconnectivity of individual mitochondrial tubules. 
Treatment of SH-SY5Y cells with 6-hydroxydopamine in the presence of MARCH5 expression 
caused a loss of mitochondrial connectivity compared to mock treated MARCH5 expressing 
cells, while treatment with 6-hydroxydopamine of MARCH5H43W expressing cells had no impact 
on mitochondrial interconnectivity compared to untreated control cells (Figure 4.3A). Using 
rotenone as inducer of neurodegenerative stress, blocking MARCH5 function through 
expression of MARCH5H43W was also able to almost completely suppress loss of mitochondrial 
interconnectivity (Figure 4.3B). As for treatment of SH-SY5Y cells with Aβ, MARCH5H43W was 
able to suppress mitochondrial fission compared to MARCH5 expressing cells and preserve 
connectivity of mitochondrial tubules at levels almost comparable to control cells (Figure 4.3C). 
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Figure 4.3: Inactive MARCH5 supports mitochondrial interconnectivity under 
neurodegenerative stress conditions. 
SH-SY5Y co-transfected with expression plasmids for PA-GFP and either MARCH5 or MARCH5H43W were treated 
with 75 µM 6-hydroxydopamine for 6 hours (A), 5µM rotenone for 6 hours (B), or 25 µM Aβ peptide for 24 hours 
(C) and mitochondrial interconnectivity was measured following activation of PA-GFP in a small area of  the 
mitochondrial network. Shown is one representative picture and the average of three independent experiments 
with 15 cells each/condition. Statistical significance was analyzed using Student’s t-test with ** marking p < 0.01. 
Error bars represent SEM.  
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To evaluate whether inactivation of MARCH5 has impact not only on mitochondrial dynamics, 
but also on mitochondrial core function under neurodegenerative stress conditions, 
mitochondrial membrane potential in MARCH5 or MARCH5H43W expressing cells following 
treatment with 6-hydroxydopamine, rotenone or Aβ was measured (Figure 4.4) with mock 
treated cells serving as control. To this end, cells were loaded with the mitochondrial 
membrane sensitive dye tetramethylrhodamine ethyl ester (TMRE) and single cell analysis of 
confocal images was performed. While expression of MARCH5 had no effect on mitochondrial 
membrane potential when compared to mitoYFP expressing control cells, expression of 
MARCH5H43W caused mitochondrial hyperpolarization (Figure 4.4A). Treatment of MARCH5 
expressing cells with 6-hydroxydopamine (Figure 4.4B), rotenone (Figure 4.4C) or Aβ (Figure 
4.4D) caused significant loss of mitochondrial membrane potential in comparison to untreated 
MARCH5 expressing cells. Also, treating MARCH5H43W expressing cells with these stressors 
resulted in a loss of mitochondrial membrane potential compared to untreated MARCH5H43W 
control cells. However, loss of membrane potential was less pronounced in MARCH5H43W 
expressing cells between stressed and unstressed conditions compared to wildtype MARCH5 
expressing cells. Comparing MARCH5 and MARCH5H43W expressing cells, the membrane 
potential in stressed MARCH5H43W cells is at levels seen in unstressed MARCH5 expressing cells. 
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Figure 4.4: Mitochondrial membrane potential under neurodegenerative stress conditions is 
increased following inactivation of MARCH5.  
(A) SH-SY5Y cells expressing mitoYFP, MARCH5-YFP or MARCH5H43W-YFP were stained with the mitochondrial 
membrane potential sensitive dye TMRE, images were taken by confocal microscopy and TMRE fluorescence as 
measure for mitochondrial membrane potential was determined using image analysis. SH-SY5Y cells expressing 
MARCH5-YFP or MARCH5H43W-YFP were treated with 75 µM 6-hydroxydopamine for 6 hours (B), 5µM rotenone for 
6 hours (C), or 25 µM Aβ peptide for 24 hours (D) and mitochondrial membrane potential was measured as in A. 
Shown is the average of three independent experiments with 10 cells each per condition. Statistical significance 
was analyzed using Student’s t-test with ** marking p < 0.01. Error bars represent SEM. 
 
To further gain insight into the mechanisms responsible for MARCH5H43W-mediated protection 
from neurodegenerative stress, cellular levels of ROS were assessed using single cell analysis of 
CellRox fluorescence. To this end, first, ROS levels were measured in cells expressing MARCH5, 
MARCH5H43W or mitoYFP and no significant difference between either group was detected 
(Figure 4.5A). Analysis of MARCH5 or MARCH5H43W expressing cells treated with 6-
hydroxydopamine revealed an increase in intracellular ROS in MARCH5 cells, while expression 
of MARCH5H43W prevented this 6-hydroxydopamine mediated spike in ROS almost completely 
(Figure 4.5B). Similarly, expression of MARCH5H43W was able to blunt ROS production following 
72 
 
treatment with rotenone, while ROS levels were elevated about 2-fold in MARCH5 expressing 
cells compared to untreated MARCH5 expressing control cells (Figure 4.5C). As for 
mitochondrial stress evoked by treatment with Aβ, ROS levels in MARCH5H43W expressing cells 
were about 50% compared to cells producing MARCH5. However, Aβ treatment caused still an 
increase in ROS even in the presence of inactive MARCH5, albeit to a lower extent compared to 
control cells. 
 
 
Figure 4.5: Inactivation of MARCH5 blunts ROS production under neurodegenerative stress 
conditions.  
(A) SH-SY5Y cells expressing mitoYFP, MARCH5-YFP or MARCH5H43W-YFP were treated with the ROS-sensitive dye 
CellROX and intracellular ROS levels were measured using image analysis of confocal pictures. SH-SY5Y cells 
expressing MARCH5-YFP or MARCH5H43W-YFP were treated with 75 µM 6-Hydroxydopamine for 6 hours (B), 5 µM 
rotenone for 6 hours (C), or 25 µM Aβ peptide for 24 hours (D) and mitochondrial membrane potential was 
measured as in A. Shown is the average of four independent experiments with 10 cells per condition. Statistical 
significance was analyzed using Student’s t-test with ** marking p < 0.01 and n.s. marking no significant difference. 
Error bars represent SEM. 
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4.4 Material and methods 
4.4.1 Cell culture  
Human neuroblastoma cell line SH-SY5Y was purchased from DSMZ. SH-SY5Y cells were 
cultured in high glucose DMEM, supplemented with 2mM L-glutamine, 1mM sodium pyruvate, 
and 15% fetal bovine serum (Sigma). Cells were incubated in a humidified incubator at 5% CO2 
and 37 °C. 
SH-SY5Y cells were transfected using Effectene (Qiagen) according to the manufacturer’s 
recommendations. To generate stably expressing SH-SY5Y cells, selection was performed using 
geneticin sulfate (400μg/ml) for 4 weeks. Degree of transfection was established using flow 
cytometric analysis (CyAn ADP, Beckman Coulter) and found to be around 80%. SH-SY5Y cells 
were treated with 6-hydroxydopamine (75μM, 6 hours), rotenone (5μM, 6 hours), and Aβ-
peptide 25-35 (Sigma A4559, 25 μM, 24 hours). 
4.4.2 Microscopy  
For immunocytochemistry, cells were seeded in 6-well plates onto glass slides at 1x104 
cells/well in 2ml culture medium. Samples were fixed using methanol-free electron microscopy 
grade 4% paraformaldehyde in PBS for 15 minutes at RT, permeabilized for 15 minutes at room 
temperature using 0.15% Trixon X-100 in PBS and blocked for 1 hour in 10% BSA in PBS. To 
visualize mitochondria, samples were then incubated with mouse anti-cytochrome c antibody 
(BD Biosciences 556432, 1:1000) overnight at 4 °C and Alexa546-conjugated anti-mouse 
antibodies (Invitrogen A11003, 1:500) for 1 hour at RT. Samples were mounted in mounting 
medium (Vectashield H1000) and observed using a confocal microscope (Zeiss LSM Meta710, 
63×/1.4 objective). For life cell imaging, cells were seeded onto chambered coverglass (Nunc 
Lab-Tek, 154461) at a density of 5x103/well in 1ml culture media. Measurement of 
mitochondrial interconnectivity was performed as described before [11]. In short, SH-SY5Y cells 
were transfected with an expression construct for photoactivatable GFP (PAGFP) and 
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mitochondrial network area following photoconversion of PAGFP employing a 405 nm laser was 
measured. To measure mitochondrial membrane potential, cells were stained with 100nM 
TMRE (Invitrogen, T-669) in media for 20 minutes at 37 °C and washed three times with media. 
Imaging was performed on a LSM710 confocal microscope (Zeiss) equipped with a live cell 
imaging chamber. Z-stacks (5 images, 1 µm distance) were acquired and image analysis was 
performed using Imaris v7.0 software (Bitplane Scientific Software). Data are expressed as 
mean signal intensity of thirty randomly selected cells per treatment group (three independent 
experiments, 10 cells each). To measure cellular ROS, cells were stained using 5µM CellROX 
Deep Red Reagent (Invitrogen, C10422) for 30 minutes at 37 °C, washed three times with PBS 
and fixed using 4% paraformaldehyde before imaging. Z-stacks (5 images at 1µm intervals) were 
acquired and analyzed using Imaris 7.0. Data are expressed as mean signal intensity of cells 
(four independent experiments, 10 cells each/group each). 
4.4.3 Statistical analysis  
Statistical analysis was performed using unpaired, two-tailed Student’s t test as implemented in 
Microsoft Excel. A p-Value of <0.05 or smaller was considered statistically significant and is 
marked with*, while p-Values of <0.01 are marked with **. Error bars represent the standard 
error of the mean (SEM). 
4.5 Discussion 
While MARCH5 is involved in the removal of proteins associated with specific 
neurodegenerative disorders such as ataxin-3 in Joseph-Machado disease or mSOD1 in 
amyotrophic lateral sclerosis likely supporting mitochondrial function, MARCH5 activity during 
general mitochondrial oxidative stress does not seem to confer a protective effect. 
Mitochondrial fragmentation in response to oxidative insults evoked by external ROS 
generators such as 6-hydroxydopamine or internal ROS generators such as rotenone or Aβ was 
greatly diminished in cells expressing MARCH5H43W, while wildtype MARCH5 did not prevent the 
75 
 
remodeling of the mitochondrial network in response to stress. Thus it is conceivable that 
during neurodegenerative stress, removal of damaged proteins from mitochondria through 
MARCH5 seems not to be as essential as one might expect from an ubiquitin ligase involved in 
mitochondrial protein quality control. Rather, the function of MARCH5 as mitochondrial 
morphogen modulating Drp1 activity might be important in this context. And indeed we 
previously showed that inactivation of MARCH5 protects neuronal cells from stress-induced cell 
death [11] likely through the inhibition of Drp1-dependent mitochondrial fragmentation in 
accordance with previous observations where inhibition of Drp1 activity strongly delayed cell 
death [16]. Thus, the function of MARCH5 in regulating mitochondrial morphology might also 
be the main factor in the here observed positive effect on mitochondrial fidelity upon 
expression of dominant-negative MARCH5H43W. Fragmentation of the mitochondrial network is 
a response to potentially lethal stress conditions such as increased oxidative stress or loss of 
membrane potential. As mitochondrial fragmentation is an integral part of the apoptotic 
program with forced fragmentation sensitizing cells to apoptotic stimuli [17], shortening 
mitochondria does not seem to have a protective effect on cells but might rather be seen as 
preparation for starting the cell death program although mitochondrial fission per se is not an 
apoptotic stimulus [5]. In contrast, elongation of mitochondria seems to be protective as 
evidenced by de-sensitization to apoptotic stimuli following increased mitochondrial fusion 
[18]. Also during stress-induced mitochondrial hyperfusion (SIMH), enhanced fusion and 
therefore highly interconnected mitochondrial tubules prove to increase resistance against 
certain stresses [19]. While most experimental stress conditions induce mitochondrial 
fragmentation, stress at levels well below the apoptotic threshold induces mitochondrial 
elongation. The SIMH-associated adaption of mitochondrial morphology is brought about in an 
Mfn1- and OPA1-dependent but Mfn2-independent manner and is likely not achieved by forced 
mitochondrial elongation due to inhibition of Drp1 function [19]. The increased 
interconnectivity during SIMH conditions mitochondria against further stress potentially by 
boosting their ATP production likely via increased availability of substrates and ETC 
intermediates in fused mitochondrial reticulum with its extended matrix space. Whether 
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inactivation of MARCH5 induces SIMH is unclear as mitochondrial elongation in the absence of 
external stress is evident in MARCH5H43W expressing cells, however, the observed increase of 
mitochondrial membrane potential in unstressed cells and the blunting of stress-induced ROS 
production point in this direction. This leaves the question, which additional pathways besides 
inhibition of Drp1-mediated fission might be influenced by MARCH5H43W as simply inhibiting 
Drp1 does not seem to evoke SIMH [19]. Based on our results, one might speculate that 
MARCH5 as upstream regulator of Drp1 is important during cellular stress responses and might 
modulate the activity of other targets besides Drp1. The notion of MARCH5 regulating other 
such targets is supported by our observation that expression of wildtype MARCH5 did not 
preserve mitochondrial function under neurodegenerative stress conditions although no effect 
on mitochondrial interconnectivity was observed [8]. Importantly, expression of MARCH5 in the 
absence of stress conditions did not impact mitochondrial membrane potential or ROS 
production further hinting to a role for MARCH5 during mitochondrial stress. Thus, based on 
our observations following dominant-negative MARCH5H43W expression and the effects of 
wildtype MARCH5, it seems conceivable that MARCH5 is involved in the decision for stress-
induced fragmentation versus protective mitochondrial elongation. Taken together, our data 
further support a role of MARCH5 in the modulation of Drp1 activity during mitochondrial 
fission and implicate MARCH5 in mitochondrial stress response pathways. As the mitochondrial 
stress response is pathophysiologically significant from diabetes to cardiovascular disease to 
neurodegeneration, blockage of MARCH5 might be an interesting therapeutic strategy. 
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5.1 Abstract 
Maintaining mitochondrial function is essential for neuronal survival and offers protection 
against neurodegeneration. Ubiquitin-mediated, proteasome-dependent protein degradation in 
the form of outer mitochondrial membrane associated degradation (OMMAD) was shown to 
play roles in maintenance of mitochondria on the level of proteostasis, but also mitophagy and 
cell death. Recently, the AAA-ATPase p97/VCP/Cdc48 was recognized as part of OMMAD acting 
as retrotranslocase of ubiquitinated mitochondrial proteins for proteasomal degradation. Thus, 
p97 likely plays a major role in mitochondrial maintenance. Support for this notion comes from 
mitochondrial dysfunction associated with amyotrophic lateral sclerosis and hereditary 
inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia 
(IBMPFD) caused by p97 mutation. Using SH-SY5Y cells stably expressing p97 or dominant-
negative p97QQ treated with mitochondrial toxins rotenone, 6-OHDA, or Aβ-peptide as model 
for neuronal cells suffering from mitochondrial dysfunction, we found mitochondrial 
fragmentation under normal and stress conditions was significantly increased upon inactivation 
of p97. Furthermore, inactivation of p97 resulted in loss of mitochondrial membrane potential 
and increased production of reactive oxygen species (ROS). Under additional stress conditions, 
loss of mitochondrial membrane potential and increased ROS production was even more 
pronounced. Loss of mitochondrial fidelity upon inactivation of p97 was likely due to disturbed 
maintenance of mitochondrial proteostasis as the employed treatments neither induced 
mitophagy nor cell death. This was supported by the accumulation of oxidatively-damaged 
proteins on mitochondria in response to p97 inactivation. Dysfunction of p97 under normal and 
stress conditions in neuron-like cells severely impacts mitochondrial function, thus supporting 
for the first time a role for p97 as a major component of mitochondrial proteostasis. 
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5.2 Introduction 
Failing mitochondrial maintenance is at the heart of neurodegeneration and associated 
neuronal death [1, 2]. To prevent the untimely death of neuronal cells, mitochondria are kept 
healthy and in shape through the complex interplay of various molecular mechanisms aimed at 
repairing mitochondrial damage on the molecular level [3] or at removing damaged 
mitochondrial subunits from the cell [4]. A key component of mitochondrial maintenance is 
quality control of damaged, dysfunctional proteins through protein degradation [5, 6]. Owed to 
the complex architecture and the endosymbiotic nature of mitochondria, several protein 
degradation mechanisms are in place to maintain proteostasis in the various mitochondrial 
compartments [7]. Recently, we and others described roles for the ubiquitin-proteasome 
system in maintaining mitochondrial function and proteostatis. E3 enzymes, namely 
MARCH5/MITOL [8, 9], MAPL/MULAN [10], IBRDC2 [11], RNF185 [12], and Parkin [13] were 
found to localize to the mitochondrial outer membrane. Furthermore, ubiquitin-dependent 
protein degradation was shown to modulate mitochondrial morphology [8, 14-16] and impact 
mitophagy [17]. In addition, quality control of mitochondria-localized poly-Q [18], amyotrophic 
lateral sclerosis associated mSOD1 as well as S-nitrosylated proteins [19] is performed by the 
ubiquitin-proteasome system. Analogous to the endoplasmic reticulum (ER) which is quality 
controlled by ER associated degradation or ERAD [20], mitochondria might be considered to be 
under control of outer mitochondrial membrane associated degradation or OMMAD [21]. 
Quality control of proteins localized to a membrane-bound organelle by the cytosolic ubiquitin-
proteasome system must involve the protein extraction from the organelle and 
retrotranslocation into the cytosol for degradation. The AAA-ATPase valosin containing protein 
VCP/p97/Cdc48 is the central component of this retrotranslocation machinery necessary for 
proteasomal degradation of organellar proteins [22]. Interestingly, p97 fulfils this function for 
ERAD [23] and OMMAD [24] alike. As such, p97 is an integral part of proteasomal quality 
control of ER-localized as well as mitochondrial proteins. While the role of p97 in maintaining 
ER proteostasis is extensively studied, the connection between p97 and mitochondrial health is 
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less clear. However, p97 dysfunction was recently linked to some forms of amyotrophic lateral 
sclerosis and hereditary inclusion body myopathy associated with Paget disease of bone and 
frontotemporal dementia (IBMPFD) and a connection to failed mitochondrial quality control 
was suspected [25]. 
To further define the role of p97 in mitochondrial maintenance especially in neuronal-like cells, 
we studied the influence of p97 inactivation on mitochondrial health and function in SH-SY5Y 
cells in comparison to known neurotoxic mitochondrial insults. We found that inactivation of 
p97 negatively impacts mitochondrial function in terms of membrane potential, reactive 
oxygen production, morphological changes, and accumulation of oxidized proteins comparably 
to treatment with the electron transport chain inhibitor rotenone, the neurotoxin 6-
hydroxydopamine as well as Alzheimer’s disease related Aβ peptide. These findings support an 
important function for p97 in maintaining neuronal health through mitochondrial protein 
quality control and further strengthen the link between mitochondrial dysfunction and 
premature neuronal death. 
5.3 Results 
5.3.1 Mitochondrial fragmentation as result of inactivation of p97 
Mitochondria fragment in response to mitochondrial insults such as the complex I inhibitor 
rotenone, the neurotoxic compound 6-hydroxydopamine (6-OHDA) or the Alzheimer’s-related 
peptide Ab. To assess whether p97 is involved in mitochondrial maintenance and stress 
protection in neuron-like cells, p97 function was blocked by overexpression of p97QQ, a 
dominant-negative version of p97, under conditions of mitochondrial insult. In order to induce 
low level mitochondrial insult, toxin concentration and time of insult was selected to minimize 
impact on cellular viability. To this end, SH-SY5Y neuroblastoma cells stably expressing p97 or 
dominant-negative p97QQ under control of a tetracycline-inducible promoter were treated with 
tetracycline in the presence of rotenone, 6-OHDA, or Ab. As shown in Figure 5.1, expression of 
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p97QQ caused mitochondrial fragmentation in 57.3 +/- 5.9% compared to 5 +/- 2% in control 
cells expressing p97 and 7 +/- 1% in uninduced p97QQ cells. Treatment of p97-expressing cells 
with the mitochondrial toxins rotenone, 6-OHDA or Ab resulted in mitochondrial fragmentation 
in 59.3 +/- 7.6%, 69 +/- 6.2% and 53.3 +/- 6.7%, respectively. Interestingly, expression of p97QQ 
in the presence of mitochondrial toxins had a strong additive effect and caused mitochondrial 
fragmentation in 92.3 +/- 3.1% (rotenone), 95 +/- 1.7% (6-OHDA), and 96.7 +/- 2.5% (Ab) of SH-
SY5Y cells. These data are consistent with a role for p97 in mitochondrial maintenance during 
normal as well as under mitochondrial stress conditions. 
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Figure 5.1: Inactivation of p97 increased mitochondrial fragmentation under stress.  
(A) SH-SY5Y cells stably expressing p97 or dominant-negative p97QQ under control of the Tet-On promoter were 
induced with tetracycline for 16 hours or left uninduced and treated with 5 µM rotenone, 75 µM 6-OHDA, or 50 
µM Aβ for 6 hours. Cells were fixed and stained using anti-cytochrome c antibody and Alexa546-conjugated 
secondary antibody. Shown are representative pictures from three independent experiments. (B) Fragmentation 
of the mitochondrial network in cells from A was quantified by visual examination. Shown is the average of three 
independent experiments. Statistical analysis was performed using pair-wise t-tests with p-value adjustment 
according to Holm. Statistical significance is marked with n.s. for not significant, *** p< 0.001. 
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5.3.2 Inactivation of p97 negatively impacts mitochondrial membrane potential 
and increases production of reactive oxygen species 
Mitochondrial membrane potential is a measure for mitochondrial health with a drop in 
membrane potential being a sign of mitochondrial dysfunction. Mitochondrial membrane 
potential was measured in neuron-like cells under conditions of mitochondrial insult during p97 
inactivation to further assess the role of p97 in maintaining mitochondrial health. To this end, 
SH-SY5Y cells stably expressing p97 or p97QQ were treated with rotenone, 6-OHDA, or Ab or left 
untreated as control and mitochondrial membrane potential was measured using the 
membrane-potential sensitive dye tetramethylrhodamine ethyl ester (TMRE). As shown in 
Figure 5.2A, ectopic expression of p97 did not impact mitochondrial membrane potential 
compared to control, while the potential was diminished to 80.6 +/- 6.0% of control by 
expression of p97QQ. Furthermore, treatment with mitochondrial toxins in addition to p97QQ 
expression caused a further reduction of mitochondrial membrane potential to 60.9 +/- 8.3% 
(rotenone), 61.5 +/- 4.6% (6-OHDA), and 62.9 +/- 5.6% (Ab). In addition to mitochondrial 
depolarization, increased production of reactive oxygen species (ROS) is a hallmark of failing 
mitochondrial maintenance and subsequent dysfunction. To further analyse the role of p97 in 
mitochondrial maintenance in neuron-like cells cells, ROS production was measured under 
mitochondrial stress conditions in the presence or absence of p97 function. Again, SH-SY5Y cells 
stably containing tetracycline-inducible p97 or p97QQ were induced with tetracycline, treated 
with rotenone, 6-OHDA, or Aβ or left untreated as control, and mitochondrial ROS levels were 
analyzed by flow cytometry using the ROS-sensitive dye MitoSox. While ectopic expression of 
p97 had only a minor influence on ROS levels (114.9 +/ 8.7%) compared to uninduced control 
cells (Figure 5.2B), expression of p97QQ alone caused ROS levels to increase to 212.7 +/- 18.7%. 
Additional treatment of p97 expressing cells with mitochondrial toxins further increased ROS 
levels to 158 +/- 8.3% (rotenone), 167.7 +/- 9% (6-OHDA), and 294.3 +/- 14.1% (Aβ). In response 
to p97 inactivation under mitochondrial stress conditions ROS levels further increased to 290.4 
+/- 55.6% (rotenone), 360.9 +/- 58.9% (6-OHDA), and 611.5 +/- 129.1% (Aβ). The observed 
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increase of ROS production following p97 inactivation and the significant additive effect on ROS 
production of inactive p97 during mitochondrial stress strongly support a crucial role for p97-
dependent mitochondrial maintenance under normal as well as stress conditions. 
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Figure 5.2: Inactivation of p97 impairs mitochondrial function during neurotoxic stress. 
(A) SH-SY5Y cells stably expressing p97 or dominant-negative p97QQ under control of the Tet-On promoter were 
induced with tetracycline for 2 hours or left uninduced and treated with 5 µM rotenone, 75 µM 6-OHDA, or 50 µM 
Aβ for an additional 6 hours. Cells were stained with the mitochondrial membrane sensitive dye TMRE and 
analyzed by flow cytometry. (B) Cells treated as in A were stained with the ROS-sensitive dye MitoSox and 
mitochondrial ROS generation was measured using flow cytometry. Statistical analysis was performed using pair-
wise t-tests with Holm p-value adjustment. Statistical significance is marked with n.s. for not significant, * p<0.05, 
** p<0.01, *** p< 0.001. 
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5.3.3 Inactivation of p97 impairs mitochondrial maintenance below the 
mitophagic threshold 
Recently, p97 was implicated in the execution of mitophagy [26]. To assess whether the 
observed mitochondrial dysfunction under the employed stress conditions and p97 inactivation 
are linked to blocked mitophagy or might be attributed to other roles of p97, Parkin 
translocation to mitochondria [13] as a marker for mitophagic induction was measured. To this 
end, SH-SY5Y cells stably expressing p97 or p97QQ were transfected with an expression 
construct for YFP-tagged Parkin, induced with tetracycline and exposed to mitochondrial insults 
by treating with rotenone, 6-OHDA, or Ab. Treatment with the protonophore (3-
Chlorophenyl)hydrazonomalononitrile (CCCP) capable of complete mitochondrial depolarization 
and subsequent Parkin translocation served as control. As shown in Figures 5.3A+B, while 
treatment with CCCP induced Parkin translocation in almost all cells, neither expression of p97 
or p97QQ, nor neurotoxin treatment at the used concentrations caused significant (< 4%) 
translocation of Parkin to mitochondria. Consistent with this finding, the employed 
concentrations of rotenone, 6-OHDA, and Ab also did not lead to cell death as measured by 
flow cytometry (Figure 5.3C), neither in the presence of ectopic p97 nor following expression of 
p97QQ. Thus, while the employed treatments with neurotoxic substances degraded 
mitochondrial function, the threshold for mitophagic induction as well as cell death was not 
reached. Therefore, the observed role for p97 in mitochondrial maintenance under the stress 
conditions employed by us is also likely on the protein degradation level rather than on the 
mitophagic or cell death level. 
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Figure 5.3: p97 is involved in mitochondrial maintenance at damage levels below the 
thresholds for mitophagy and cell death. 
(A) SH-SY5Y cells stably expressing p97 or dominant-negative p97QQ under control of the Tet-On promoter were 
transfected with an expression construct for YFP-tagged Parkin, induced with tetracycline for 2 hours or left 
uninduced and treated with 5 µM rotenone, 75 µM 6-OHDA, or 50 µM Aβ for an additional 6 hours. Cells were 
fixed, stained for the mitochondrial marker cytochrome c (cyt. C) and Parkin translocation from the cytosol to 
mitochondria was visually analyzed using fluorescence microscopy. Shown are representative images of three 
independent experiments. (B) Shown is a quantification of Parkin translocation from the cytosol to mitochondria 
from A. (C) Cells treated as in A were stained with the cell impermeable dye 4',6-diamidino-2-phenylindole (DAPI) 
and the percentage of dead cells was determined by flow cytometry. Statistical analysis was performed using pair-
wise t-tests with p-value adjustment according to Holm. Statistical significance is marked with *** p< 0.001. In C 
no statistical significance was observed. 
 
5.3.4 p97 is involved in clearing oxidatively -damaged proteins from 
mitochondria 
To further support this notion, the ubiquitin- and p97-mediated proteasome-dependent 
turnover of oxidized mitochondrial proteins under mitochondrial stress conditions was 
measured. In SH-SY5Y cells ectopically expressing p97, treatment with neither rotenone, nor 6-
OHDA or Ab significantly increased levels of oxidized proteins compared to untreated control 
cells (Figure 5.4, for representative western blots see Figure 5.S1). Interestingly, in p97QQ 
expressing cells, levels of oxidized mitochondrial proteins were significantly increased (p < 
0.001) compared to p97 expressing cells confirming a function for p97 in the removal of 
oxidatively-damaged mitochondrial proteins. Furthermore, levels of oxidized proteins 
significantly increased in p97QQ expressing cells under mitochondrial stress conditions due to 
rotenone, 6-OHDA, and Ab treatment compared to p97QQ control cells. Again, these data are 
consistent with the involvement of p97 in the degradation of damaged proteins to maintain 
mitochondrial function in neuron-like cells under mitochondrial stress conditions below the 
threshold of mitophagic induction or cell death. 
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Figure 5.4: Clearance of oxidatively-damaged mitochondrial proteins is impaired following 
inactivation of p97.  
SH-SY5Y cells stably expressing p97 or dominant-negative p97QQ under control of the Tet-On promoter were 
induced with tetracycline for 2 hours or left uninduced and treated with 5 µM rotenone, 75 µM 6-OHDA, or 50 µM 
Aβ for an additional 6 hours. Mitochondria were isolated using anti-TOMM22 magnetic beads resulting in highly 
purified mitochondria. Protein carbonylation as measure for oxidative damage was determined by infrared laser-
based quantitative western blotting following derivatization with 2,4-Dinitrophenylhydrazine (DNPH) and 
detection using anti-DNP antibodies. Shown is the average of three independent experiments. Please see Figure S1 
for representative western blot images. Statistical analysis was performed using pair-wise t-tests with p-value 
adjustment according to Holm. Comparisons shown are tetracycline-induced, untreated cells vs. tetracycline-
induced, treated cells. Statistical significance is marked with n.s. for not significant, *** p< 0.001. 
 
5.4 Discussion 
Mechanisms of mitochondrial maintenance act on the cellular level by removing complete 
dysfunctional mitochondrial networks through programmed cell death. On the organellar level 
they act through mitophagic degradation of dysfunctional mitochondrial subunits and finally on 
the molecular level by repairing and/or removing damaged mitochondrial components such as 
DNA, lipids or proteins [7]. While programmed cell death is an effective means to rid the body 
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of damaged and, due to their excessive ROS production, potentially harmful mitochondrial 
networks, in post-mitotic neurons excessive apoptotic cell death is equivalent to 
neurodegeneration [27]. Thus, mitophagy and degradation of damaged proteins are likely the 
first lines of defence against mitochondrial dysfunction in neurons as neuronal death is avoided. 
Which mechanism, mitophagy or protein degradation is more prevalent in neurons under 
normal conditions remains unclear. However, it is conceivable that the removal of individual 
components such as damaged proteins from otherwise functional mitochondria might be 
preferable to the destruction of whole mitochondrial subunits. Especially under conditions of 
everyday stress, with slowly accumulating, low overall mitochondrial damage, keeping 
mitochondrial damage below the mitophagic threshold through the constant removal of 
damaged proteins is likely to prevent neuronal damage. 
Using known mitochondrial toxins such as rotenone, 6-OHDA, and Aβ at concentrations and 
treatment times below the threshold of cell death and mitophagic induction, we intended to 
model the above mentioned low level stress and evaluate the importance of p97 and 
associated protein degradation as well as its influence on mitochondrial fidelity in neuronal 
cells. Interestingly, inactivation of p97 alone – without additional exogenous stress - for as little 
as eight hours negatively influenced mitochondrial morphology, membrane potential and ROS 
production. Although p97 has many cellular functions and pleiotropic effects of p97 inactivation 
have to be taken into account, these observations are consistent with a direct role for p97 in 
mitochondrial maintenance under normal conditions in the absence of external mitochondrial 
stress. This notion is further supported by the accumulation of oxidatively-damaged 
mitochondrial proteins following p97 inactivation. Even under normal conditions without 
exogenous mitochondrial stress, a considerable amount of oxidized protein is present in 
mitochondria and significantly accumulates as consequence of a short period of p97 
inactivation. Thus, in the absence of any detectable mitophagic activity, continuous turnover of 
damaged mitochondrial proteins occurs in a p97-dependent manner. As p97 is an ubiquitin-
dependent chaperone, this is consistent with constantly ongoing mitochondrial maintenance in 
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neuronal cells through the ubiquitin-proteasome system under normal, unstressed conditions. 
Consistent with this finding, we recently connected p97 and oxidatively-damaged proteins to 
outer mitochondrial membrane associated degradation or OMMAD, the ubiquitin-dependent, 
proteasome-mediated degradation mitochondrial proteins (ref: 25062828). Further support to 
this notion is lent by the effect of p97 inactivation under exogenous stress conditions below the 
mitophagic threshold. Concurrent stress and p97 inactivation had additive effects on 
mitochondrial fragmentation, membrane potential, ROS production as well as the accumulation 
of oxidatively-damaged mitochondrial proteins. These observations again support a function for 
p97 in dealing with mitochondrial damage to keep dysfunction of mitochondria below the 
threshold above which mitophagic degradation or even cell death occurs. Thus, we propose 
that constant repair of mitochondrial damage by the ubiquitin-proteasome system in a p97-
dependent manner even under conditions of no or low exogenous mitochondrial stress is 
critically important for maintaining mitochondrial function under normal conditions. 
Mitophagic clearance on the other hand might be responsible for maintaining mitochondrial 
function in response to more drastic insults likely not encountered under normal conditions. 
Taken together, p97-mediated mitochondrial proteostasis is likely an important mechanism to 
prevent mitochondrial dysfunction as result of slowly accruing mitochondrial damage under 
normal conditions and to keep associated neurodegenerative processes at bay. 
5.5 Material and methods 
5.5.1 DNA constructs 
To generate a vector for the one-step generation of stable, tetracycline-inducible human cell 
lines, the CMV promoter in the AAVS1 donor cloning vector DC-DON-SH01 (Genome-TALER™ 
human AAVS1 safe harbor gene knock-in kit, GeneCopoeia) was replaced by the hybrid 
CMV/Tet-On promoter originating from pcDNA5/FRT/TO (Invitrogen) with MluI/PmeI. 
Afterwards, a stuffer sequence with 5' PmeI site followed by EcoRV site and 3' BstBI site was 
inserted using PmeI, BstBI to generate pAN2066. To enable tetracycline regulation of the 
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construct, the GFP coding region in pAN2066 was replaced with the coding sequence of the 
tetracycline repressor. To this end, the bGH poly-A-Ef1α-GFP fragment was amplified from DC-
DON-SH01 using ATTCGACTCGAGTTCGAATTTAAATCGGATCCCT and 
ATTCGAGATATCGATCCGGTGGAGCCGGG and cloned into pBluescript SK (+) with XhoI/EcoRV to 
create pAN2067. Next, GFP was replaced by TetR amplified using PCR from pcDNA6/TR 
(Invitrogen) with ATTCGAAAGCTTGTGAGTTTGGGGACCCTTG and 
ATTCGAGATATCGCATAAGATCTGAATTCCCGGGA and inserted HindIII/EcoRV to generate 
pAN2070. Fragment bGH poly-A-Ef1α-TetR was released from pAN2070 with BstBI/EcoRV and 
transferred to pAN2066 cut with BstBI/NruI to obtain pAN2071. Then, p97 or p97QQ (gift from S. 
Fang) was amplified by PCR using GACTCGGATATCATGGCTTCTGGAGCCGATTCAA and 
TGTAACAACGTTTTAGCCATACAGGTCATCATCATCATT and cloned EcoRV/BstBI into pAN2071. 
5.5.2 Cell culture and generation of cell lines 
SH-SY5Y cells were cultured in 5% CO2 incubator at 37°C in high glucose DMEM (Sigma, D6546) 
containing 15% Tet System Approved FBS (Clontech, 631106), supplemented with 2mM L-
glutamine (Sigma, G5713), and 1mM sodium pyruvate (Sigma, G7513). To generate stably 
transfected SH-SY5Y cells expressing p97 or p97QQ under control of the Tet-On promoter, cells 
were transfected using Effectene (Qiagen, 301425) according to manufacturer’s 
recommendations with two TALEN constructs for the PPP1R2C or AAVS1 “safe harbor” locus 
and an expression construct containing p97 or p97QQ under control of the Tet-On promoter as 
well as a puromycin resistance gene to enable selection. For stably transfected cells, 0.75μg/ml 
puromycin was added to maintain selection (Invivogen, ant-pr-1). Expression of p97 or p97QQ 
was induced by treatment with 1μg/ml tetracycline (Roth, Hp63.1). Mitochondrial stress was 
induced by treatment with 5µM rotenone (Sigma, R8857), 75µM 6-hydroxdopamine (Sigma, 
H8523) or 50µM amyloid-β protein fragment 25-35 (Sigma, A4559). 
5.5.3 Flow cytometry 
95 
 
Flow cytometry was performed using a CyAn ADP Analyzer (Beckman Coulter). SH-SY5Y cells 
grown in 6 well cell culture plates (Sarstedt) and induced and/or treated as indicated were co-
stained with DAPI and either 10nM TMRE (Invitrogen) for 30 minutes at 37 °C, or 5 µM 
MitoSOXTM (Invitrogen) for 10 minutes at 37 °C. Cells were harvested, washed twice in PBS and 
resuspended in 1 ml PBS containing 0.5 % (w/v) BSA and 50µM EDTA. Flow cytometry was 
performed immediately afterwards. Data analysis was performed using FlowJo v.10. Sequential 
gating was performed as follows (with identical gates used for each experiment): cells were 
gated for using logarithmic forward/sideward scatter axes; doublet discrimination was 
performed using forward scatter area/forward scatter followed by pulse width/forward scatter 
dot plots. Dead cells were excluded in DAPI/forward scatter dot plots. 
5.5.4 Isolation of mitochondria 
The human mitochondria isolation kit (Miltenyi Biotec, 130-094-532) was used according to 
manufacturer’s instructions. Briefly, cells were harvested and either directly processed or 
stored overnight in liquid nitrogen. All following steps were performed on ice with pre-cooled 
buffers. Cells were resuspended in 800µl lysis buffer supplemented with protease inhibitors 
(1µg/ml pepstatin; 1µg/ml leupeptin; 1mM PMSF) and 50µM EDTA. Cells were passed 15 times 
through a 25 gauge needle. Nine ml separation buffer and 50µl Anti-TOMM22 MicroBeads were 
added to the cell homogenate before rotating the suspensions for 1 hour at 4 °C. Magnetic 
separation was performed using a MACS Separator. Purified mitochondria were immediately 
lysed in RIPA buffer (Thermo Scientific) supplemented with protease inhibitors (1µg/ml 
pepstatin; 1µg/ml leupeptin; 1mM PMSF) and 50µM EDTA and subjected to five 10 second 
intervals of sonication at 10 kHz. Total protein content was measured using the Pierce BCA 
protein assay kit (Thermo Scientific) and was immediately followed by DNPH labeling. 
5.5.5 Labeling with DNPH 
Labeling with DNPH was performed according to [28] with minor alterations. Briefly, 60µg of 
total protein in 20µl total volume was added to 20µl 12 % sodium dodecyl sulfate (SDS). 40µl of 
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20mM DNPH in 2M HCl were added, samples were briefly mixed and incubated for 15 minutes. 
To control for DNPH-reactive protein carbonyls, samples were reacted with 2M HCl lacking 
DNPH. 30µl of 2M Tris base, 30 % glycerol and a final concentration of 50mM 1,4-Dithiothreit 
were added to stop the reaction. Samples were briefly mixed again and immediately used for 
SDS PAGE. 
5.5.6 Western Blot 
DNPH-labeled protein lysates were resolved by SDS PAGE (5µg total protein per lane were 
loaded) and blotted onto nitrocellulose membrane (Whatman). Fast Green FCF (Sigma Aldrich, 
F7252) was used to evaluate total protein loaded per lane as follows: nitrocellulose membranes 
were stained for 10 minutes in Fast Green FCF staining solution (0.001 % FCF, 30 % methanol, 7 
% acetic acid), followed by 10 minutes in destaining solution (30 % methanol, 7 % acetic acid) 
and then 10 minutes in water. An infrared laser scanner (LiCor) was used for detection of FCF. 
Following Fast Green FCF, membranes were blocked for 1 hour in 3% (w/v) Top Block (Lubio 
science, TB232010) in PBS-Tween 20 (0.05%) and immune-detection using polyclonal rabbit 
anti-DNP antibodies (D9656 Sigma, 1:2000) and polyclonal goat anti-rabbit Dylight 800 (35521 
Pierce, 1:6000) was performed and detected using an infrared laser scanner (LiCor) to obtain 
quantitative measurement. Each experiment was performed three times independently and 
each measurement was performed in triplicates. Image analysis was performed using ImageJ 
[29]. 
5.5.7 Microcopy 
Cells were seeded in 6-well plates onto glass slides at 1x104 cells/well in 2ml culture medium. 
Samples were fixed using methanol-free electron microscopy grade 4% paraformaldehyde in 
PBS for 15 minutes at RT, permeabilized for 15 minutes at RT using 0.15% Trixon X-100 in PBS 
and blocked for 1 hour in 10% BSA (w/v) in PBS. To visualize mitochondria, samples were then 
incubated with mouse anti-cytochrome c antibody (BD Biosciences 556432, 1:1000) overnight 
at 4 °C and Alexa546-conjugated anti-mouse antibodies (Invitrogen A11003, 1:500) for 1 hour at 
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RT. Nuclei were stained by incubation with DAPI (Invitrogen, D1306, 1:1000) for 5 minutes right 
after Alexa546 incubation. Samples were mounted in mounting medium (Vectashield, H1000) 
and observed using a confocal microscope (Zeiss LSM Meta710, 63×/1.4 objective). 
Mitochondria fragmentation and Parkin-to-mitochondria translocation were assessed visually 
and quantified as percentage of control. The extend of mitochondrial fragmentation was judged 
based on comparison to untreated control cells with mitochondrial networks scored as 
fragmented if most mitochondria in a cell did no longer exhibit an elongated phenotype. All 
experiments were performed independently in triplicates. 
5.5.8 Statistical analysis 
Statistical significance of differences was assessed using pair-wise t-tests with the adjustment 
for multiple comparisons according to Holmes as implemented in R [30]. Significance is 
indicated with n.s. p>0.05, * for p<0.05, ** for p<0.01, and *** for p<0.001. 
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5.6 Supplementary material 
Supplementary Figure 5.S1: Detection of carbonylated mitochondrial proteins. 
SH-SY5Y cells stably expressing p97 or dominant-negative p97QQ under control of the Tet-On 
promoter were induced with tetracycline for 2 hours or left uninduced and treated with (A) 
vehicle, (B) 5µM rotenone, (C) 75µM 6-OHDA, or (D) 50µM Aβ for an additional 6 hours. 
Mitochondria were isolated using anti-TOMM22 magnetic beads resulting in highly purified 
mitochondria. Mitochondrial proteins were derivatized using DNPH and analyzed by western 
blotting. Total protein was determined using Fast Green FCF staining and quantified using an 
infrared laser-based scanner. Protein oxidation was determined using anti-DNP antibody-based 
detection of DNPH-derivatized carbonylated proteins and also quantified by using infrared laser 
scanning. Shown is one representative membrane (three technical and three biological 
replicates) stained using Fast Green FCF to visualize total protein loading (upper panel) followed 
by anti-DNP western blotting (lower panel). The bars mark the areas quantified using image 
analysis. 
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Figure 5.S1: Representative western blots for detecting carbonylated mitochondrial proteins. 
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6 Conclusions  
Due to the energetic sensitivity and structural constraints of neuronal cells, mitochondrial 
maintenance is thought to be essential for neuronal health. Within the scope of this study, 
we have investigated the role of MARCH5 and p97 in mitochondrial quality control and their 
connection to neuronal health through the use of in vitro neuronal cell-like models.  
6.1 Cellular models 
Two cellular models representing cells with neuronal characteristics were used during the 
course of these studies. While neuron-like cell lines have limitations with regards to their 
applicability to the in vivo situation, they still proved very useful to decipher basing 
biochemical and cell biological pathways present in neuronal cells. The first cell line employed 
in our studies is the RGC-5 cell line. RGC-5 was first reported in 2001 [25], as immortalized 
line derived from rat retinal ganglion cells (RGCs), constituting one of the most promising 
cellular models for retina ganglion degeneration research. Hundreds of studies have been 
performed based on the ganglion cells character of  RGC-5 cells [24]. Subsequently, further 
examination of RGC-5 revealed that this cell line was derived from 661W cells, a mouse 
retinal photoreceptor cell line [208]. While this invalidated RGC-5 cells as bona fide model for 
retinal ganglion cells, RGC-5 are still considered neuron-like cells and demonstrate several 
features representative for of neuronal cells, especially after certain differentiation stimulus. 
For instance, RGC-5 express neuron-specific markers, such as Tau, βIII-tubulin, microtubule-
associated protein (MAP)-1b, MAP2, and PGP9.5 [209]. In addition, treatment with 
staurosporine (STS) or trichostatin A can terminally transform RGC-5 leading to a neuron-like 
phenotype [210]. 
As a second model for neuron-like cells, the human neuroblastoma cell line SH-SY5Y was 
employed. SH-SY5Y represents a sub-clonal population derived from SK-N-SH, an isolate from 
a bone marrow biopsy taken from a four year-old female with neuroblastoma. SH-SY5Y is 
104 
 
reported to steadily express dopaminergic neuronal markers, such as tyrosine hydroxylase 
(TH), dopamine receptor 2 and 3 subtypes (D2R and D3R), and dopamine transporter (DAT) 
[211, 212], and SH-SY5Y is also reported to feature acetylcholinergic, glutamatergic and 
adenosinergic phenotypes [212, 213]. Those features let to the use of SH-SY5Y cells as cellular 
model neuronal cells and these cells are widely used [214]. 
6.2 Neurodegenerative stressors 
In order to mimic conditions of neurodegeneration in the employed cellular models of 
neuronal-like cells, exogenous stressors were applied. As neurodegeneration is a slowly 
progressing process, we reasoned that low stress conditions might most faithfully replicate 
the in vivo situation in terms of mitochondrial dysfunction and levels of oxidative stress. Our 
hypothesis was that under normal, everyday conditions slowly accumulating mitochondrial 
damage is likely taken care of by the molecular levels of mitochondrial maintenance rather 
than mitophagic destruction of entire mitochondrial subunits. To this end, different stressors 
were applied at concentrations at which it was reasonable to assume that the molecular level 
of mitochondrial maintenance is engaged. To this end, the levels of mitochondrial stress were 
chosen based on the lack of induction of mitophagy or even cell death. The following agents 
with known impact on mitochondrial function were employed. First, the agricultural 
pesticide, mitochondrial complex I inhibitor rotenone was used. Rotenone is known to inhibit 
the transfer of electrons from iron-sulfur centers in complex I to ubiquinone, thus 
interrupting the electron transport chain and negatively impacting ATP production. The block 
in the ETC in turn leads to the premature transfer of electrons to oxygen leading to ROS 
production [215]. Animal experiments showed that injection of rotenone into rats induces 
Parkinson-like symptoms, while cellular studies demonstrated that rotenone treatment 
induced oxidative damage and cell death in dopaminergic neurons [29, 216]. As another 
stressor, 6-hydroxidopamine (6-OHDA), a compound designed to selectively enter 
dopaminergic or noradrenergic neurons through dopamine and noradrenaline reuptake 
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transporters, known to induce intracellular oxidative stress in neuronal cells [28]. Application 
of 6-OHDA in animal models elicits mimics Parkinson’s disease and serves as PD model to 
study disease mechanisms and to test  potential medications[217]. As third mitochondrial 
stress, amyloid β (Aβ(1-42)) protein, a major component of Alzheimer’s disease-associated 
amyloid plaques, was employed to induce mitochondrial dysfunction in neuron-like cells 
[218]. While the exact mode of action for Aβ is unknown, it is accepted that Aβ is crucially 
involved in the development of AD [219, 220]. However, some potential explanations for Aβ 
neurotoxic activity are discussed in the literature. A relationship between ubiquitin-
proteasome system function and the clearance of Aβ aggregates has been widely discussed 
[221]. Also, it was postulated that the mitochondrial quality control system is involved in Aβ 
pathogenesis as well [222]. Aβ (25-35) peptide, one of the most toxic derivatives of Aβ, has 
lower molecular weight and more water soluble than Amyloid-β (1-42) [223]. Studies showed 
that Aβ (25-35) peptide originating form extracellular aggregates are able to induce oxidative 
stress and neuronal cell apoptosis, and induce AD-related neuron functional impairment 
similar as the full-length Amyloid-β (1-42) [30, 224, 225].  
6.3 MARCH5 
The mitochondrial ubiquitin ligase MARCH5 is implicated in various mitochondrial processes 
and seems to fulfill two major functions, namely the degradation of various mitochondrial 
proteins as well as the modulation of mitochondrial fission. It was shown that MARCH5 is able 
to modulate mitochondrial morphology by influencing Drp1 activity and therefore fission of 
mitochondrial tubules [16]. In detail, it was shown that expression of dominant-negative 
MARCH5H43W, a RING domain mutant of MARCH5, inhibits mitochondrial fission and causes 
highly fused and interconnected mitochondrial networks. In addition and in contrast to wild 
type MARCH5, MARCH5H43W co-localizes with Drp1 on mitochondria in a focal fashion. These 
MARCH5H43W/Drp1 containing mitochondrial foci were speculated to represent blocked 
mitochondrial fission sites. Thus, MARCH5 is modulator of mitochondrial fission and 
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therefore potentially involved in the organellar level of mitochondrial maintenance. Also, as 
fission is strongly connected to the induction of apoptosis, MARCH5 function is likely involved 
to apoptotic induction with inactive MARCH5 likely acting anti-apoptotic.  
Aside its clear function in mitochondrial fission, MARCH5 is also involved in the molecular 
level of mitochondrial quality control by clearing mutated or damaged protein aggregates in 
neuronal cells, such as mutated SOD1 and polyglutamine (polyQ) [19, 20]. Mutated SOD1 is a 
misfolded, mitochondria-localized protein that is involved in the pathology of the 
neurodegenerative disorder amyotrophic later sclerosis (ALS) [226], while accumulation of 
polyQ proteins is the cause of polyQ diseases such as Machado–Joseph disease, another 
neurodegenerative disorder [227]. In addition, excessive nitro oxide (NO) will cause cellular 
stress through S-nitrosylation of target proteins. It was shown that MARCH5 is involved in the 
degradation of S-nitrosylated microtubule-associated protein 1B-light chain (MAP1B-LC1 
connecting MARCH5 to mitochondria intracellular transport mechanisms [205]. These 
observations strongly connect MARCH5 to mitochondrial protein degradation pathways and 
potentially to degradation processes important to the health of neuronal cells. Recently, it 
was reported that the mitofusin Mfn2 is a substrate of MARCH5 [131]. Aside its function in 
mitochondrial fusion, Mfn2 is a key factor of mitochondria-endoplasmic reticulum (ER) 
membrane cross talk involved in calcium buffering. In this case, MARCH5 regulates the 
function of Mfn2 and is involved in mitochondria-ER cross talk potentially interesting for 
neurodegeneration as mis-balanced calcium homeostasis is harmful to neuronal cells [228]. 
Despite the interesting connections between MARCH5-mediated protein degradation and 
neuronal health and neurodegenerative processes, no direct involvement of MARCH5 in 
neurodegenerative diseases has been shown to date. Given the two main functions of 
MARCH5, degradation of toxic mitochondrial proteins and the regulation of mitochondrial 
fusion, it is not clear which of these functions contributes more to general mitochondrial 
maintenance under normal conditions. Especially, as these two functions might contribute 
differently to the outcome of MARCH5-mediated mitochondrial maintenance. MARCH5-
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mediated protein degradation is part of the molecular levels of mitochondrial maintenance 
with the potential to rescue individual mitochondrial subunits, while MARCH5-mediated 
mitochondrial fission might be involved in organellar-level maintenance or might even 
promote apoptotic cell death. 
In this study, the influence of MARCH5 inhibition on the outcome of neurotoxic stress was 
assessed in neuron-like in vitro models using MARCH5H43W to modulate MARCH5 activity.  
Under the stress conditions employed in the present study, neuron-like cells with expression 
of MARCH5H43W featured inhibited mitochondrial fragmentation compared to control cells 
where stress-induced mitochondrial fission was evident. The prevention of mitochondrial 
fragmentation and preservation of an interconnected network served to maintain 
mitochondrial function, kept excessive ROS production at bay, and reduced cell death. Based 
on previous studies, the protective effect of MARCH5H43W exerted in our cell model can be 
attributed to the role of MARCH5 in the regulation of mitochondrial dynamic namely its 
interaction with the pro-fission protein Drp1 [16, 17, 127]. This conclusion is supported by the 
observation that blocking Drp1 function under the same stress condition conferred similar 
protective effects to neuron-like cells. It is likely that the MARCH5H43W-induced highly fused 
mitochondrial network in neuron-like cells induced strengthens the abilities of these cells to 
deal with mitochondrial stress. Interestingly, stress-induced mitochondrial hyperfusion [104] 
also protects cells from further insult supporting the notion that fused mitochondrial 
networks are more stress resistant than single mitochondrial subunits. As for the function of 
MARCH5 in the degradation of neuro-toxic proteins, it seems that under the stress conditions 
employed this function of MARCH5 did not seem to contribute to the observed maintenance 
of mitochondrial function. It remains unclear whether MARCH5 function in terms of protein 
degradation is inhibited in cells expressing MARCH5H43W and it therefore remains uncertain to 
what extent MARCH5-dependent protein degradation on mitochondria is involved in 
protecting mitochondria against neuro-toxic stressors. However, it is reasonable to assume 
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that the function of MARCH5 in modulating mitochondrial dynamics plays an important role 
in protecting neuron-like cells during neuro-toxic insult.  
6.4 p97 
The AAA-ATPase and chaperone p97 is involved in a plethora of cellular functions among the 
ubiquitin-dependent protein quality control [229]. IBMPFD or Inclusion Body Myopathy 
associated with Paget’s disease of the Bone and Fronto-Temporal Dementia is caused by 
mutations in p97 [230, 231]. Interestingly, a mitochondrial component for the progression of 
IBMPFD is discussed [232, 233]. In addition, in vitro studies have shown that certain p97 
mutations induce mitochondrial uncoupling and decreased ATP production [232]. 
Furthermore, p97 was connected to mitochondrial quality control via PINK/parkin-dependent 
mitophagic pathways, together with the adaptor protein Npl4/Ufd1 [234].   
Also recently, p97 was connected to mitochondrial maintenance and degradation of 
mitochondrial proteins likely as part of the retrotranslocase responsible for the extraction of 
ubiquitylated proteins from mitochondria. It was shown that p97 is essential for the 
degradation of mitochondrial Mcl-1 [145, 235] and also damaged proteins such as 
carbonylated and S-nitrosylated mitochondrial proteins in a proteasome-depended manner 
preserving mitochondrial functions [236, 237].  In the present study, multiple low dose neuro-
toxic treatments were applied to SH-SY5Y cells under conditions of inactive p97. Here, a 
critical role of p97 in preserving mitochondrial function in neuron-like cells was identified. 
Especially a role for p97 in clearing carbonylated mitochondrial proteins as part of 
mitochondrial QC was confirmed. The data presented here clearly supports a role for p97 in 
mitochondrial maintenance also in neuronal cells. Taken together, it is reasonable to assume 
that the mitochondrial role of p97 is indeed essential for neuronal survival and that proper 
functioning of p97 on mitochondria acts neuroprotective. This adds an additional function to 
the already busy AAA-ATPase p97 and firmly connects this important chaperone involved in 
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ubiquitin-dependent degradation of damaged or superfluous proteins also to mitochondrial 
protein degradation and quality control. 
6.5 Summary 
In this in vitro study connections between mitochondrial maintenance and mitochondrial 
function in neuron-like cells were explored to gain insight into mechanisms of 
neurodegeneration. Our results confirm the strong link between mitochondrial maintenance 
and processes impairing the function of neuronal cells. It was shown that effective and 
sufficient mitochondrial quality control system is critical to neuronal cell survival. Also, our 
findings strongly support the importance of removing damaged proteins from mitochondria 
in order to maintain their overall function, a process not well studied and underappreciated 
in the past. Taken together, novel insight into mechanisms of mitochondrial maintenance is 
import to better understand mitochondrial dysfunction and its connection to 
neurodegenerative processes and to devise novel therapeutic approaches to fight these 
diseases. 
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